<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Mild cognitive impairment: Prognosis and treatment</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Mild cognitive impairment: Prognosis and treatment</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Mild cognitive impairment: Prognosis and treatment</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ronald C Petersen, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Steven T DeKosky, MD, FAAN, FACP, FANA</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Janet L Wilterdink, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 30, 2021.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Mild cognitive impairment (MCI) is an intermediate clinical state between normal cognition and dementia. While specific subtle changes in cognition are frequently observed in normal aging, there is increasing evidence that some forms of cognitive impairment are recognizable as an early manifestation of a neurodegenerative condition that will ultimately lead to dementia [<a href="#rid1">1</a>].</p><p>The utility of this paradigm centers around the recognition that there is a continuum of cognition between normal aging and dementia, and dementia represents a rather advanced state of cognitive impairment. </p><p>This topic will review the prognosis and treatment of MCI. The epidemiology, pathology, and clinical assessment of MCI and topics related to dementia, including diagnosis, treatment, risk factors, and prevention of dementia, are discussed separately. (See  <a class="medical medical_review" href="/d/html/5081.html" rel="external">"Mild cognitive impairment: Epidemiology, pathology, and clinical assessment"</a> and  <a class="medical medical_review" href="/d/html/5073.html" rel="external">"Treatment of Alzheimer disease"</a> and  <a class="medical medical_review" href="/d/html/5079.html" rel="external">"Risk factors for cognitive decline and dementia"</a> and  <a class="medical medical_review" href="/d/html/5075.html" rel="external">"Prevention of dementia"</a> and  <a class="medical medical_review" href="/d/html/5071.html" rel="external">"Clinical features and diagnosis of Alzheimer disease"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">PROGRESSION TO DEMENTIA</span><span class="headingEndMark"> — </span>Older adults with MCI are at increased risk for progressing to dementia. Across multiple studies, those with MCI are approximately three times more likely to develop dementia over the next two to five years compared with age-matched controls [<a href="#rid2">2</a>].</p><p>On the other hand, a certain percentage of patients with MCI improve, even to normal, over a one- to three-year follow-up time, especially if a treatable cause of the MCI is identified [<a href="#rid3">3-8</a>]. The proportion who do improve ranges from 14 to 56 percent across various studies [<a href="#rid2">2</a>]. This finding emphasizes the expected clinical heterogeneity of MCI. However, such patients remain at significantly increased risk for a future diagnosis of dementia compared with those who have never received a diagnosis of MCI [<a href="#rid8">8-10</a>]. In spite of short-term clinical instability of the diagnosis, the vast majority of persons once labeled with MCI will progress to dementia [<a href="#rid9">9,10</a>].</p><p>Part of the variability between studies is due to the different populations studied, for example, patients referred to memory clinics versus epidemiologic cohorts [<a href="#rid11">11</a>].</p><p>Alzheimer disease (AD) and other forms of dementia are associated with increased mortality. In one community health center-based cohort study, MCI was associated with a small increased mortality hazard (hazard ratio [HR] 1.2) [<a href="#rid12">12</a>]. Other studies have also found that the presence and severity of MCI are associated with reduced survival [<a href="#rid13">13</a>]. </p><p class="headingAnchor" id="H3"><span class="h2">Rates of progression</span><span class="headingEndMark"> — </span>When counseling patients age 65 years and older who are diagnosed with MCI that is suspected to be of neurodegenerative origin, we estimate the risk of progression to dementia to be 10 percent per year and 15 percent over two years. </p><p>The overall incidence rate of dementia in the general older adult population is estimated at 1 to 3 percent per year [<a href="#rid5">5,14,15</a>]. By contrast, reported annual rates of progression from MCI to dementia have ranged from 5 to 16 percent, with lower rates of progression observed in population-based studies and higher rates in clinical centers and some treatment trials [<a href="#rid4">4-6,14-25</a>]. Rates of conversion also vary according to the duration of follow-up; one analysis compared longer-duration (&gt;5 years) with shorter-duration studies and found lower rates with longer durations of follow-up, suggesting that the risk of conversion decreases over time [<a href="#rid26">26</a>]. In this study, the cumulative incidence was 33 percent. Typically, patients convert within a period of two to three years; however, longer intervals of up to eight years have been reported [<a href="#rid27">27</a>].</p><p class="headingAnchor" id="H4"><span class="h2">Predictors</span><span class="headingEndMark"> — </span>Given the heterogeneity of outcomes among individuals with MCI, many studies have investigated factors that might identify those with MCI who will develop dementia. Combinations of risk factors may be more predictive than individual risk factors [<a href="#rid28">28</a>]. A formula using multiple variables for predicting MCI in the general population has been described but has not been independently validated [<a href="#rid29">29</a>]. </p><p>Sex and education level have not been consistently shown to be predictive of progression to dementia [<a href="#rid25">25,30</a>]. Individual risk factors that are more consistently associated with this risk are discussed in the following sections. Risk factors for dementia in the general population are discussed separately. (See  <a class="medical medical_review" href="/d/html/5079.html" rel="external">"Risk factors for cognitive decline and dementia"</a>.)</p><p class="headingAnchor" id="H2487810966"><span class="h3">Age</span><span class="headingEndMark"> — </span>Aging is a primary predictor of progression of MCI to AD [<a href="#rid4">4,22,31-35</a>]. With every year of age increase, MCI is slightly more likely to convert to AD. </p><p>In persons younger than 50 years, MCI is relatively unlikely to represent a predementia condition [<a href="#rid22">22</a>], unless there is a family history of early-onset dementia associated with an autosomal dominant mutation.</p><p class="headingAnchor" id="H2116473307"><span class="h3">Neuropsychological testing</span><span class="headingEndMark"> — </span>A variety of observational studies suggest that neuropsychological testing is helpful in defining individuals with MCI who are at risk for dementia. Patients who meet MCI criteria according to neuropsychological test performance have a higher rate of conversion to dementia than those who have a clinical dementia rating (CDR) scale summary score of 0.5 (<a class="graphic graphic_table graphicRef53706" href="/d/graphic/53706.html" rel="external">table 1</a>), which is based on an office assessment of cognition and daily functioning [<a href="#rid36">36</a>].</p><p>More severely affected patients (with greater deficits and/or a broader range of deficits on neuropsychological testing) have been shown to be at greater risk for dementia than those who are less affected, according to prospective cohort studies of patients [<a href="#rid6">6,37-43</a>]. Deficits that include a primary or prominent amnestic component as well as those that lead to slight impairment in daily functioning are also felt to identify patients at higher risk of dementia [<a href="#rid44">44</a>]. </p><p>A number of specific test measures, such as delayed verbal recall, visual recognition memory, and other cued memory tasks, as well as measures of instrumental activities of daily living, have also been found to have high predictive value for dementia in some studies [<a href="#rid28">28,33,38,45-53</a>]. However, these have not been independently and prospectively validated in a manner that allows application to individual cases.</p><p>Follow-up neuropsychological testing may provide more helpful information regarding prognosis; a decrement in performance compared with prior testing is more sensitive than comparison with group norms [<a href="#rid54">54</a>]. However, the sensitivity and specificity of certain patterns of decline have not been rigorously evaluated. Educational level is an important modulator of test performance and rate of decline [<a href="#rid39">39,41,54-56</a>]. Practice effects, which can lead to test score improvement in normal older adults even after an interval of one to two years, may decrease the sensitivity of neuropsychological test decline as a predictor of AD [<a href="#rid57">57</a>]. Practice effects can be seen in normal subjects, but they tend to be short lived [<a href="#rid58">58</a>].</p><p class="headingAnchor" id="H7"><span class="h3">Psychological features</span><span class="headingEndMark"> — </span>Neuropsychiatric symptoms are prevalent in individuals with MCI. (See  <a class="medical medical_review" href="/d/html/5081.html" rel="external">"Mild cognitive impairment: Epidemiology, pathology, and clinical assessment", section on 'Neuropsychiatric symptoms'</a>.)</p><p>Whether the presence of such features is predictive of conversion to dementia is uncertain. Studies with different designs, follow-up periods, and inclusion of nonamnestic types of MCI (naMCI) have found increased [<a href="#rid59">59-62</a>], decreased [<a href="#rid63">63,64</a>], or no change in the risk [<a href="#rid65">65</a>] of dementia when MCI is associated with depression. Other studies have suggested that apathy, anxiety, and dysphoria may be harbingers of incipient MCI [<a href="#rid66">66-68</a>].</p><p class="headingAnchor" id="H8"><span class="h3">APOE epsilon 4</span><span class="headingEndMark"> — </span>At this time, testing of apolipoprotein E (<em>APOE</em>) genetic status is not recommended in MCI patients. </p><p><em>APOE</em> epsilon 4 (ε4) genotype has been associated with the risk of MCI and AD in the general population but has had mixed association with conversion to AD dementia among individuals with MCI. (See  <a class="medical medical_review" href="/d/html/16195.html" rel="external">"Genetics of Alzheimer disease", section on 'Apolipoprotein E'</a> and  <a class="medical medical_review" href="/d/html/5081.html" rel="external">"Mild cognitive impairment: Epidemiology, pathology, and clinical assessment", section on 'Epidemiology'</a>.)</p><p>Some studies have found that <em>APOE</em> ε4 is a strong risk factor for conversion from MCI to AD [<a href="#rid19">19,34,38,69-72</a>], but others have found only a marginal or even no association [<a href="#rid30">30,31,33,73-75</a>]. A meta-analysis of 35 prospective cohort studies found a moderate association of <em>APOE</em> ε4 and progression to AD (OR = 2.3), but low sensitivity (0.53) and positive predictive value (0.57) [<a href="#rid76">76</a>]. </p><p class="headingAnchor" id="H7911102"><span class="h3">Cerebrovascular risk factors</span><span class="headingEndMark"> — </span>Studies of the impact of vascular risk factors on the conversion of MCI to dementia have had variable results [<a href="#rid70">70,77-79</a>]. </p><p>Evidence of cerebrovascular disease on magnetic resonance imaging (MRI) has also been associated with a higher risk of conversion to dementia. (See <a class="local">'MRI'</a> below.)</p><p class="headingAnchor" id="H9"><span class="h3">CSF biomarkers</span><span class="headingEndMark"> — </span>Because the pathologic processes of AD and other degenerative dementias are likely well underway before clinical symptoms manifest, biomarkers would seem to have potential utility in the early diagnosis of dementia. However, these tests do not have an established role in the evaluation of patients with MCI in the clinical setting [<a href="#rid2">2</a>]. </p><p>A number of smaller studies have examined the use of cerebrospinal fluid (CSF) markers for predicting conversion from MCI to dementia [<a href="#rid28">28,47,80,81</a>]. The CSF biomarkers most often found to be predictive include:</p><p class="bulletIndent1"><span class="glyph">●</span>Increased levels of tau or tau protein phosphorylated at Thr 181 [<a href="#rid21">21,34,82-90</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Lower levels of amyloid beta 42 (Aß42) peptide, a low ratio of Aß42 to Aß40 levels, and a low ratio of Aß42 to tau levels [<a href="#rid21">21,85-87,89,91-103</a>] </p><p></p><p>A 2014 meta-analysis of 14 observational studies evaluating CSF Aß42 as a tool for predicting conversion from MCI to AD found significant variation in assay thresholds, which precluded summary estimates of sensitivity and specificity [<a href="#rid104">104</a>]. Sensitivity in individual studies ranged from 36 to 100 percent and specificity ranged from 29 to 91 percent. The authors concluded that a low CSF Aß42 is of marginal clinical utility. The absence of a clinical treatment imperative for MCI makes this relatively invasive test less appealing at this point in time. New CSF analytical platforms are being developed to standardize the measurements of key analytes for predicting conversion from MCI due to AD to dementia due to AD.</p><p class="headingAnchor" id="H10"><span class="h3">Plasma biomarkers</span><span class="headingEndMark"> — </span>Ongoing investigations are focusing on biomarkers in the serum or plasma that correlate with AD and other neurodegenerative dementias. An analysis of 120 signaling proteins in blood plasma found 18 that could be used to classify healthy controls from patients with AD [<a href="#rid105">105-107</a>]. These were then studied in a series of 47 patients with MCI; these proteins identified 20 of 22 patients who developed clinical AD and none of the eight patients who developed non-AD dementia. Seven of 17 patients with stable MCI at follow-up had proteins suggestive of AD and continue to be followed for possible future progression to AD. The replicability of plasma markers for predicting progression has been a challenge; however, studies using mass spectrometry are particularly encouraging [<a href="#rid108">108,109</a>].</p><p class="headingAnchor" id="H11"><span class="h3">Neuroimaging</span><span class="headingEndMark"> — </span>Pathologic studies have shown that the earliest and most severe neurofibrillary manifestations of AD are found in the medial temporal lobe. Neuroimaging studies have focused attention on these and other areas to define structural abnormalities that may predict conversion from MCI to AD, as these appear to be more closely associated with MCI than other findings, such as white matter abnormalities [<a href="#rid110">110</a>].</p><p class="headingAnchor" id="H3031623"><span class="h4">MRI</span><span class="headingEndMark"> — </span>Regional atrophy and cerebrovascular disease can be identified on MRI in cognitively normal patients who later develop dementia [<a href="#rid111">111,112</a>]. The more abnormalities present, the more likely a person is to progress. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Temporal lobe atrophy</strong> may be an early specific marker for preclinical AD; similar patterns of temporal lobe atrophy are seen in patients with amnestic MCI (aMCI) and AD, but are not seen in individuals with multiple-domain naMCI, whose scans (at least in one study) are similar to healthy controls [<a href="#rid113">113-115</a>]. While most studies use specialized techniques for volumetric measurements, visual assessment using a standardized rating scale seems to perform nearly as well [<a href="#rid116">116-118</a>]. Efforts are underway to develop automated structural MRI techniques that allow patterns of atrophy to be quantitatively assessed [<a href="#rid119">119</a>].</p><p></p><p class="bulletIndent1">Both the degree and progression of medial temporal lobe atrophy on MRI are associated with conversion to dementia in patients with MCI as well as in people with normal baseline cognition [<a href="#rid28">28,30,33,53,75,86,87,90,116-118,120-138</a>]. These changes can be observed one to two years prior to cognitive decline and, at least in one study, are better predictors of future AD than CSF biomarkers [<a href="#rid87">87</a>]. Similarly, higher baseline apparent diffusion coefficient (ADC) values in the hippocampus on diffusion-weighted MRI (DWI) may predict conversion to dementia in patients with aMCI [<a href="#rid139">139,140</a>]. Older age, <em>APOE</em> ε4, and poorer baseline cognition predicted progressive hippocampal atrophy in one study of patients with MCI [<a href="#rid141">141</a>]. Other longitudinal follow-up studies have found that thinning of the temporal and parietal cortex as determined by MRI morphometric analysis may be useful in predicting conversion from MCI to AD [<a href="#rid135">135,142,143</a>]. At least one study has suggested that a finding of temporal lobe atrophy is prognostically useful even when the underlying process is judged to be non-Alzheimer related [<a href="#rid144">144</a>].</p><p></p><p class="bulletIndent1">However, there is overlap in the degree of atrophy for patients who do and do not progress to dementia, and the same is true for ADC values. While these findings are not clearly predictive of progression to dementia for individual patients, nonetheless, of the available markers, these MRI findings appear to be most proximate to conversion to dementia [<a href="#rid87">87,145-147</a>]. We note these findings as a marker of higher risk when we counsel patients.</p><p></p><p class="bulletIndent1">Similarly, while some investigations suggest that these MRI changes may be useful in combination with other risk factors in predicting risk of AD, such multivariate models require independent validation [<a href="#rid87">87,127</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>An increased extent of subcortical white matter hyperintensities</strong> and/or cortical infarction on MRI has been associated with MCI in some studies [<a href="#rid112">112,114,148-155</a>]. In one study of 170 individuals with MCI, vascular subcortical hyperintensities predicted the risk of vascular or mixed dementia over a median follow-up of four years [<a href="#rid156">156</a>]. More longitudinal studies are needed to assess whether an MRI finding of white matter hyperintensities or cerebral infarction represents a risk factor for further cognitive decline or progression to dementia [<a href="#rid137">137</a>].</p><p></p><p>The combination of these abnormalities may be more predictive of future dementia than their individual presence. In a longitudinal study of the very old, MRI markers of hippocampal atrophy and white matter hyperintensities were both independent predictors of conversion to AD over a two-year period [<a href="#rid157">157</a>]. However, the number of subjects who progressed to AD with a single imaging abnormality was small. </p><p class="headingAnchor" id="H434537656"><span class="h4">Amyloid PET</span><span class="headingEndMark"> — </span>Amyloid positron emission tomography (PET) tracers (<a class="drug drug_general" data-topicid="83331" href="/d/drug information/83331.html" rel="external">florbetapir F-18</a>; <a class="drug drug_general" data-topicid="91387" href="/d/drug information/91387.html" rel="external">flutemetamol F-18</a>; <a class="drug drug_general" data-topicid="94523" href="/d/drug information/94523.html" rel="external">florbetaben F-18</a>; Pittsburgh Compound B C11, PiB) that measure amyloid lesion burden in the brain have been developed as tools to aid in the diagnosis of AD in vivo, aid in early diagnosis and prognosis, speed development of anti-amyloid medications, and differentiate AD from other causes of dementia. (See  <a class="medical medical_review" href="/d/html/5071.html" rel="external">"Clinical features and diagnosis of Alzheimer disease", section on 'Neuroimaging'</a>.) </p><p>While many F-18 compounds have been approved by the US Food and Drug Administration (FDA) for qualitative assessment of beta amyloid plaque density, they are not intended for use as a diagnostic agent in patients with dementia and are not universally available or reimbursed by all insurers. While a negative amyloid scan makes it extremely unlikely that a symptomatic person with dementia has AD, there is ongoing uncertainty about the predictive value of a positive scan for individuals with both normal cognition and MCI.</p><p>The prevalence of cerebral amyloid pathology on PET in adults with normal cognition as well as MCI varies by age and <em>APOE</em> status. In a meta-analysis of patient-level data from 55 studies of amyloid PET in 8694 adults, the prevalence of a positive amyloid PET scan rose progressively by decade among patients with normal cognition: 10 percent at 50 years of age, 16 percent at 60 years, 23 percent at 70 years, 33 percent at 80 years, and 44 percent at 90 years [<a href="#rid158">158</a>]. Among individuals with MCI, the prevalence of a positive scan was also higher at each decade, ranging from 27 percent at 50 years of age to 71 percent at 90 years. <em>APOE</em> ε4 carriers were two to three times more likely to have a positive scan than noncarriers.</p><p>Longitudinal follow-up studies of patients with MCI have shown that those with amyloid tracer retention have a higher rate of progression to dementia than those who do not [<a href="#rid138">138,159-165</a>], with an estimated sensitivity for conversion to AD of 83 to 100 percent but lower specificity (46 to 88 percent) [<a href="#rid166">166</a>]. Higher C11-PiB retention appeared in one study to correlate with a more rapid rate of progression [<a href="#rid160">160</a>]. In one cohort study, the combination of a positive <a class="drug drug_general" data-topicid="91387" href="/d/drug information/91387.html" rel="external">flutemetamol F-18</a> labeled PET, low hippocampal volumes on MRI, and cognitive status consistent with aMCI identified a high probability of progression to dementia in 36 months [<a href="#rid167">167</a>].</p><p>More studies with longer follow-up times, more patients, and pathologic correlation are needed to define the prognostic value of amyloid PET imaging in patients with MCI. In all likelihood, amyloid PET will prove to be most useful in combination with other biomarkers. In a study that evaluated the relative value of the various imaging modalities in predicting progression from MCI to dementia due to AD, the presence of amyloid coupled with evidence of neurodegeneration (hippocampal atrophy on MRI or FDG-PET hypometabolism) showed the highest likelihood of progression [<a href="#rid168">168</a>]. </p><p class="headingAnchor" id="H3431760607"><span class="h4">FDG-PET</span><span class="headingEndMark"> — </span>Identification of regional patterns of cortical hypometabolism using 18-F fluorodeoxyglucose PET (FDG-PET) may be useful for predicting conversion from MCI to AD, especially in the presence of the <em>APOE</em> ε4 allele [<a href="#rid169">169-175</a>]. In one cohort, abnormal results on PET combined with impaired episodic memory identified a group 11.7 times more likely to convert to AD compared with individuals who tested normally on both measures [<a href="#rid100">100</a>]. However, PET studies alone only marginally predicted cognitive decline in this patient group. A systematic review of 14 studies examining the value of FDG-PET in predicting the conversion of MCI to AD found that specificity was highly variable across studies, and there was no defined threshold for determination of test positivity [<a href="#rid176">176</a>]. This emphasizes the need to consider any diagnostic testing and prognostication in MCI in the context of the clinical encounter [<a href="#rid177">177</a>]. The limited availability of PET in most medical centers is a current obstacle to widespread use.</p><p class="headingAnchor" id="H2912484957"><span class="h4">Tau PET imaging</span><span class="headingEndMark"> — </span>Tau PET imaging has become available and is being investigated, and the tracer, <a class="drug drug_general" data-topicid="128354" href="/d/drug information/128354.html" rel="external">flortaucipir F-18</a>, was approved by the FDA in 2020. Tau PET may offer an important diagnostic tool for predicting cognitive decline. However, more data are needed to document the clinical utility of tau PET imaging in predicting progression from MCI to dementia [<a href="#rid178">178-180</a>]. </p><p class="headingAnchor" id="H4128719014"><span class="h3">Other risk factors</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Slow gait </strong>–<strong> </strong>Combined with cognitive complaints, gait slowing may identify individuals at higher risk of MCI and future dementia [<a href="#rid181">181-183</a>]. Some have proposed calling this state the motoric cognitive risk (MCR) syndrome, defined as the presence of cognitive complaints and slow gait in older individuals without dementia or mobility disability [<a href="#rid181">181</a>].</p><p></p><p class="bulletIndent1">In a study that pooled data from four prospective cohort studies totalling 4812 individuals without baseline dementia, MCR was associated with a twofold increased risk of both incident cognitive impairment and dementia over a mean follow-up time ranging from five to nine years [<a href="#rid182">182</a>]. Slow gait was defined as a walking speed ≥1 standard deviation below age- and sex-specific means on a timed-walk test over a fixed distance. Forty percent of individuals with MCR also met criteria for MCI, and both MCR and MCI predicted incident cognitive impairment when examined in the same multivariate model (adjusted HRs 1.63 and 1.36, respectively). While MCR was associated with the AD dementia subtype in two of the four cohorts in this study [<a href="#rid182">182</a>], it has been associated with vascular dementia in other studies [<a href="#rid181">181</a>]. Across 22 cohorts worldwide, the pooled prevalence of MCR among older adults is 10 percent [<a href="#rid182">182</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Olfactory dysfunction</strong> – Olfactory dysfunction has also been identified as a predictor or prodrome of subsequent AD dementia, both in older individuals with normal cognition and in those with MCI [<a href="#rid184">184-189</a>]. One study used the Brief Smell Identification Test (B-SIT), a scratch-and-sniff card containing six food- and six nonfood-related smells, to assess olfactory function in a population-based cohort of older adults aged 70 to 89 years with normal baseline cognition (n = 1430) or MCI (n = 221) [<a href="#rid184">184</a>]. Over a median follow-up time of three years, patients with amnestic MCI (aMCI) in the lowest quartile of olfactory function (B-SIT scores 0 to 5) had fivefold higher risk of progression to AD dementia compared with those in the highest quartile (B-SIT scores 10 to 12). Among individuals with normal cognition at baseline, B-SIT scores in the lowest quartile conferred a twofold higher risk of aMCI and no additional risk for naMCI. The associations remained significant after adjusting for baseline cognitive scores and other risk factors, including <em>APOE</em> status.</p><p></p><p class="headingAnchor" id="H13"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>This section covers studies that specifically evaluated treatments for MCI. Treatment of dementia is discussed separately. (See  <a class="medical medical_review" href="/d/html/5073.html" rel="external">"Treatment of Alzheimer disease"</a> and  <a class="medical medical_review" href="/d/html/5080.html" rel="external">"Management of the patient with dementia"</a>.)</p><p>For all patients with MCI, we treat reversible causes of cognitive impairment and modify vascular risk factors; we also inform patients of the potential benefits of exercise and cognitive interventions.</p><p class="headingAnchor" id="H1718004525"><span class="h2">Treat reversible causes</span><span class="headingEndMark"> — </span>A substantial minority of patients with MCI improve or remain stable over time. In addition, some patients have reversible causes of cognitive impairment that may be responsible for some or all of their deficits. Therefore, all patients with MCI should be evaluated and treated for reversible causes of cognitive impairment, including [<a href="#rid2">2</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Medication side effects (see  <a class="medical medical_review" href="/d/html/5079.html" rel="external">"Risk factors for cognitive decline and dementia", section on 'Medications'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Sleep disturbances (see  <a class="medical medical_review" href="/d/html/5079.html" rel="external">"Risk factors for cognitive decline and dementia", section on 'Obstructive sleep apnea'</a> and  <a class="medical medical_review" href="/d/html/5079.html" rel="external">"Risk factors for cognitive decline and dementia", section on 'Sleep disturbances'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Depression (see  <a class="medical medical_review" href="/d/html/1719.html" rel="external">"Diagnosis and management of late-life unipolar depression"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Vitamin B12 deficiency or hypothyroidism</p><p></p><p class="headingAnchor" id="H676156846"><span class="h2">Vascular risk factor modification</span><span class="headingEndMark"> — </span>Patients with MCI should be screened and treated for vascular risk factors, especially hypertension. Modification of vascular risk factors may ameliorate the risk of cognitive decline in patients with MCI [<a href="#rid190">190</a>]. Cerebrovascular disease is felt to play a role in Alzheimer disease (AD) as well as vascular dementia. (See  <a class="medical medical_review" href="/d/html/16575.html" rel="external">"Epidemiology, pathology, and pathogenesis of Alzheimer disease", section on 'Acquired risk factors'</a>.) </p><p>There have been no randomized controlled clinical trials to support this; however, treatment of hypertension has been shown to reduce the incidence of dementia in the general population, particularly in midlife [<a href="#rid191">191</a>]. There is less compelling evidence for the efficacy of antiplatelet therapy, statin therapy, smoking cessation, and diabetes management in the treatment or prevention of dementia; nonetheless, these are recommended for other health benefits. Specific treatments are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/5086.html" rel="external">"Treatment of vascular cognitive impairment and dementia"</a>.)</p><p class="headingAnchor" id="H2630040432"><span class="h2">Aducanumab</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="131816" href="/d/drug information/131816.html" rel="external">Aducanumab</a> is a recombinant monoclonal antibody directed against amyloid beta. The US Food and Drug Administration (FDA) approved aducanumab for the treatment of mild AD using the accelerated approval pathway [<a href="#rid192">192</a>]. Postapproval trials are required to verify a clinical benefit.</p><p>The clinical trials that supported the approval of <a class="drug drug_general" data-topicid="131816" href="/d/drug information/131816.html" rel="external">aducanumab</a> included patients with MCI attributed to AD as well as those with mild AD dementia (Mini-Mental State Examination [MMSE] &gt;24, clinical dementia rating [CDR] score of 0.5, and positive amyloid positron emission tomography [PET] scan). Most patients in these trials had MCI rather than dementia. Thus, we will consider such patients eligible for treatment with aducanumab. </p><p>Specific details regarding patient selection for treatment with <a class="drug drug_general" data-topicid="131816" href="/d/drug information/131816.html" rel="external">aducanumab</a>, along with dosing and monitoring guidelines, are discussed separately. (See  <a class="medical medical_review" href="/d/html/5073.html" rel="external">"Treatment of Alzheimer disease", section on 'Aducanumab'</a>.) </p><p class="headingAnchor" id="H591140343"><span class="h2">Nonpharmacologic interventions</span></p><p class="headingAnchor" id="H1716303989"><span class="h3">Exercise</span><span class="headingEndMark"> — </span>Exercise programs ranging in duration from 6 to 12 months have shown modest benefit in some measures of cognitive function in small trials. A meta-analysis of 11 randomized trials in a total 1497 participants with MCI found that aerobic exercise improved global cognitive ability by 1 point on the MMSE (95% CI 0.5-1.45) and was associated with small improvements on tests of immediate and delayed recall but not other domains [<a href="#rid193">193</a>]. Trials have generally measured short-term outcomes, and it is not known whether exercise programs affect rates of conversion from MCI to dementia. Nonetheless, because regular exercise has other health benefits and generally limited risk, many experts recommend exercise programs for patients with MCI [<a href="#rid2">2</a>].</p><p class="headingAnchor" id="H18053957"><span class="h3">Cognitive interventions</span><span class="headingEndMark"> — </span>Various modalities of cognitive rehabilitation including memory training, the use of external memory cues, and organizational aids have been shown to improve function in healthy older adults [<a href="#rid194">194-196</a>]. (See  <a class="medical medical_review" href="/d/html/5075.html" rel="external">"Prevention of dementia", section on 'Lifestyle and activity'</a>.)</p><p>It is not clear if individuals with MCI may benefit from similar programs [<a href="#rid197">197,198</a>]. Although multiple small studies have demonstrated short-term improvements in various cognitive domains after cognitive training programs compared with a control condition, the benefits tend to be small, and studies that have measured long-term outcomes generally demonstrate waning effects over time.</p><p class="headingAnchor" id="H14"><span class="h2">Not recommended or unproven</span><span class="headingEndMark"> — </span>No medications or dietary supplements have been shown to have symptomatic or preventive benefits in patients with MCI [<a href="#rid2">2,199-201</a>].</p><p class="headingAnchor" id="H15"><span class="h3">Acetylcholinesterase inhibitors</span><span class="headingEndMark"> — </span>Acetylcholinesterase inhibitors are <strong>not</strong> routinely recommended for patients with MCI [<a href="#rid190">190,202</a>]. Clinical trials of <a class="drug drug_general" data-topicid="9383" href="/d/drug information/9383.html" rel="external">donepezil</a>, <a class="drug drug_general" data-topicid="8739" href="/d/drug information/8739.html" rel="external">galantamine</a>, and <a class="drug drug_general" data-topicid="9529" href="/d/drug information/9529.html" rel="external">rivastigmine</a> in the treatment of MCI have not provided support for the use of acetylcholinesterase inhibitors in preventing progression of MCI to dementia [<a href="#rid20">20,202-208</a>]. Systematic reviews and meta-analyses of available studies have concluded that in patients with MCI, there is no evidence that treatment with cholinesterase inhibitors affects progression to dementia or improves cognitive test scores, and that there is significant evidence of an increased of treatment-associated adverse events, particularly gastrointestinal [<a href="#rid199">199,209</a>]. </p><p>However, if memory difficulties are particularly troublesome to an individual patient, a trial of <a class="drug drug_general" data-topicid="9383" href="/d/drug information/9383.html" rel="external">donepezil</a> or other acetylcholinesterase inhibitor for symptomatic benefit may be warranted [<a href="#rid20">20</a>]. Patients and families should be informed of the potential adverse effects. The risks and benefits of acetylcholinesterase inhibitors in the treatment of dementia are discussed separately. (See  <a class="medical medical_review" href="/d/html/5072.html" rel="external">"Cholinesterase inhibitors in the treatment of dementia"</a>.)</p><p class="headingAnchor" id="H16"><span class="h3">Anti-inflammatory agents</span><span class="headingEndMark"> — </span>The rationale for using anti-inflammatory agents in patients with MCI is based on the evidence of an inflammatory component to the pathogenesis of AD, as well as some epidemiologic studies suggesting that nonsteroidal anti-inflammatory drug (NSAID) use in the general population is associated with a lower risk of AD. However, there is no evidence for the benefit of NSAIDs in the treatment of MCI. (See  <a class="medical medical_review" href="/d/html/5075.html" rel="external">"Prevention of dementia", section on 'NSAID therapy'</a>.)</p><p>In a large, randomized, controlled trial of 1457 patients with MCI, treatment with rofecoxib was not associated with a lower conversion rate to dementia at four years, nor did it affect secondary endpoint measures of cognition [<a href="#rid210">210</a>].</p><p class="headingAnchor" id="H434541273"><span class="h3">Herbs and nutritional supplements</span><span class="headingEndMark"> — </span>There are no studies that suggest a benefit for herbal therapies or nutritional supplements in patients with MCI.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ginkgo biloba</strong> – A clinical trial evaluating the effects of ginkgo biloba in preventing dementia in cognitively normal older adults and those with MCI found no benefit for treatment in preventing cognitive decline or the development of dementia among individuals with MCI [<a href="#rid211">211,212</a>]. In a clinical trial of 2854 patients aged 70 years and older with memory complaints (not necessarily meeting criteria for MCI), treatment with gingko biloba (120 mg twice per day) was not associated with a reduced incidence of dementia after five years of treatment [<a href="#rid213">213</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Phospholipids </strong>–<strong> </strong>Alterations in neuronal plasma membrane lipid content and structure have been observed in the aging brain and in AD dementia [<a href="#rid214">214-216</a>]. As a result, there has been interest in using precursors of the phospholipid membrane (eg, phosphatidylserine [PS] and phosphatidylcholine [PC]) as a way of repairing the plasma membrane and improving neuronal function. PC may also act as a precursor to acetylcholine metabolism.</p><p></p><p class="bulletIndent1">Evidence of benefit in adults with cognitive impairment is currently lacking, however. There have been no trials of PS or PC in adults with strictly defined MCI. Several small trials have examined phospholipid supplementation in adults with AD, subjective memory problems, or age-related memory impairment. Results have been mixed, with some studies showing an apparent benefit [<a href="#rid217">217-222</a>] and others finding no effect [<a href="#rid221">221</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Multinutrient supplements</strong> – A randomized trial of a dietary supplement containing fish oil; uridine monophosphate; choline; vitamins B12, B6, C, E, and <a class="drug drug_general" data-topicid="8475" href="/d/drug information/8475.html" rel="external">folic acid</a>; phospholipids; and <a class="drug drug_general" data-topicid="9884" href="/d/drug information/9884.html" rel="external">selenium</a> showed no benefit on a composite cognitive performance outcome at 24 months in 311 patients with MCI due to AD [<a href="#rid223">223</a>]. The trial was limited by relatively high attrition and a smaller-than-expected change in the primary outcome over 24 months in both arms.</p><p></p><p class="headingAnchor" id="H57555165"><span class="h3">Others</span></p><p class="bulletIndent1"><span class="glyph">●</span>Transdermal nicotine was evaluated as a treatment for amnestic MCI (aMCI) in a placebo-controlled randomized study of 74 nonsmoking patients [<a href="#rid224">224</a>]. After six months of treatment, transdermal nicotine was associated with improvement in cognitive measures but not in ratings of clinician-rated global impression of change (CGIC).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Intranasal insulin was compared with placebo in 104 adults with aMCI or mild to moderate dementia [<a href="#rid225">225</a>]. After four months, treatment for the combined group of aMCI and AD was associated with improved measures of memory, Alzheimer Disease Assessment Scale-Cognitive subscale (ADAS-cog) score, and functional abilities, suggesting that further study of this therapy is warranted [<a href="#rid226">226</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Growth hormone-releasing hormone was evaluated in a clinical trial in nondemented adults, including 66 with MCI; 20 weeks of therapy was associated with improved performance on cognitive tests compared with placebo [<a href="#rid227">227</a>]. Longer-term studies are needed to evaluate the safety and efficacy of this treatment approach.</p><p></p><p class="headingAnchor" id="H2257777619"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/116344.html" rel="external">"Society guideline links: Cognitive impairment and dementia"</a>.)</p><p class="headingAnchor" id="H3546515"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/d/html/16423.html" rel="external">"Patient education: Mild cognitive impairment (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topic (see  <a class="medical medical_patient" href="/d/html/736.html" rel="external">"Patient education: Dementia (including Alzheimer disease) (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H22"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with mild cognitive impairment (MCI), particularly amnestic MCI (aMCI), are at risk for progression to dementia. A conservative estimate of the risk is 10 percent per year. Many, but not all, patients will progress to dementia due to Alzheimer disease (AD) or vascular cognitive impairment. (See <a class="local">'Progression to dementia'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Neuropsychological test measures, cerebrospinal fluid (CSF) biomarkers, and neuroimaging studies are being evaluated as predictive tools for assessing patients' risk for conversion to dementia. These lack standardization, and there is no clinical imperative for general use. Apolipoprotein E epsilon 4 (<em>APOE</em> ε4) genotype testing is also not recommended as a way to predict likelihood of progression. (See <a class="local">'Predictors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>All patients with MCI should be evaluated and treated for reversible causes of cognitive impairment, including medication side effects, sleep disturbances, depression, vitamin B12 deficiency, and hypothyroidism. (See <a class="local">'Treat reversible causes'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with MCI attributed to AD may be eligible for treatment with <a class="drug drug_general" data-topicid="131816" href="/d/drug information/131816.html" rel="external">aducanumab</a>. Patient selection is discussed separately. (See  <a class="medical medical_review" href="/d/html/5073.html" rel="external">"Treatment of Alzheimer disease", section on 'Aducanumab'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with MCI and clinical or radiologic evidence of cerebrovascular pathology should be screened and treated for vascular risk factors. This approach has not been shown to alter conversion to dementia; however, there is convincing benefit for reduction of cerebrovascular and cardiovascular events. (See <a class="local">'Vascular risk factor modification'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Regular exercise might have cognitive benefits in patients with MCI and is encouraged in older adults for general health benefits. (See <a class="local">'Exercise'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Based on the available clinical trial data and lack of convincing benefit, we suggest <strong>not</strong> routinely treating MCI with cholinesterase inhibitors (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). For an individual patient with troublesome memory difficulties, a trial of <a class="drug drug_general" data-topicid="9383" href="/d/drug information/9383.html" rel="external">donepezil</a> for symptomatic benefit may be warranted, although controlled study support for this recommendation is not available. Patients and families should be informed of the potential risks. (See <a class="local">'Treatment'</a> above.)</p><p></p><p class="headingAnchor" id="H2001378530"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Eric M McDade, DO, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Bennett DA, Wilson RS, Schneider JA, et al. Natural history of mild cognitive impairment in older persons. Neurology 2002; 59:198.</a></li><li><a class="nounderline abstract_t">Petersen RC, Lopez O, Armstrong MJ, et al. Practice guideline update summary: Mild cognitive impairment: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology 2018; 90:126.</a></li><li><a class="nounderline abstract_t">Ritchie K, Artero S, Touchon J. Classification criteria for mild cognitive impairment: A population-based validation study. Neurology 2001; 56:37.</a></li><li><a class="nounderline abstract_t">Ganguli M, Dodge HH, Shen C, DeKosky ST. Mild cognitive impairment, amnestic type: An epidemiologic study. Neurology 2004; 63:115.</a></li><li><a class="nounderline abstract_t">Larrieu S, Letenneur L, Orgogozo JM, et al. Incidence and outcome of mild cognitive impairment in a population-based prospective cohort. Neurology 2002; 59:1594.</a></li><li><a class="nounderline abstract_t">Palmer K, Wang HX, Bäckman L, et al. Differential evolution of cognitive impairment in nondemented older persons: results from the Kungsholmen Project. Am J Psychiatry 2002; 159:436.</a></li><li><a class="nounderline abstract_t">Wahlund LO, Pihlstrand E, Jönhagen ME. Mild cognitive impairment: experience from a memory clinic. Acta Neurol Scand Suppl 2003; 179:21.</a></li><li><a class="nounderline abstract_t">Koepsell TD, Monsell SE. Reversion from mild cognitive impairment to normal or near-normal cognition: risk factors and prognosis. Neurology 2012; 79:1591.</a></li><li><a class="nounderline abstract_t">Roberts RO, Knopman DS, Mielke MM, et al. Higher risk of progression to dementia in mild cognitive impairment cases who revert to normal. Neurology 2014; 82:317.</a></li><li><a class="nounderline abstract_t">Lopez OL, Becker JT, Chang YF, et al. Incidence of mild cognitive impairment in the Pittsburgh Cardiovascular Health Study-Cognition Study. Neurology 2012; 79:1599.</a></li><li><a class="nounderline abstract_t">Petersen RC, Roberts RO, Knopman DS, et al. Mild cognitive impairment: Ten years later. Arch Neurol 2009; 66:1447.</a></li><li><a class="nounderline abstract_t">Sachs GA, Carter R, Holtz LR, et al. Cognitive impairment: an independent predictor of excess mortality: a cohort study. Ann Intern Med 2011; 155:300.</a></li><li><a class="nounderline abstract_t">Wilson RS, Aggarwal NT, Barnes LL, et al. Biracial population study of mortality in mild cognitive impairment and Alzheimer disease. Arch Neurol 2009; 66:767.</a></li><li><a class="nounderline abstract_t">Petersen RC, Smith GE, Waring SC, et al. Mild cognitive impairment: Clinical characterization and outcome. Arch Neurol 1999; 56:303.</a></li><li><a class="nounderline abstract_t">Boyle PA, Wilson RS, Aggarwal NT, et al. Mild cognitive impairment: risk of Alzheimer disease and rate of cognitive decline. Neurology 2006; 67:441.</a></li><li><a class="nounderline abstract_t">Manly JJ, Tang MX, Schupf N, et al. Frequency and course of mild cognitive impairment in a multiethnic community. Ann Neurol 2008; 63:494.</a></li><li><a class="nounderline abstract_t">Busse A, Hensel A, Gühne U, et al. Mild cognitive impairment: Long-term course of four clinical subtypes. Neurology 2006; 67:2176.</a></li><li><a class="nounderline abstract_t">Plassman BL, Langa KM, Fisher GG, et al. Prevalence of cognitive impairment without dementia in the United States. Ann Intern Med 2008; 148:427.</a></li><li><a class="nounderline abstract_t">Tschanz JT, Welsh-Bohmer KA, Lyketsos CG, et al. Conversion to dementia from mild cognitive disorder: The Cache County Study. Neurology 2006; 67:229.</a></li><li><a class="nounderline abstract_t">Petersen RC, Thomas RG, Grundman M, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 2005; 352:2379.</a></li><li><a class="nounderline abstract_t">Hansson O, Zetterberg H, Buchhave P, et al. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 2006; 5:228.</a></li><li><a class="nounderline abstract_t">Visser PJ, Kester A, Jolles J, Verhey F. Ten-year risk of dementia in subjects with mild cognitive impairment. Neurology 2006; 67:1201.</a></li><li><a class="nounderline abstract_t">Fischer P, Jungwirth S, Zehetmayer S, et al. Conversion from subtypes of mild cognitive impairment to Alzheimer dementia. Neurology 2007; 68:288.</a></li><li><a class="nounderline abstract_t">Lopez OL, Kuller LH, Becker JT, et al. Incidence of dementia in mild cognitive impairment in the cardiovascular health study cognition study. Arch Neurol 2007; 64:416.</a></li><li><a class="nounderline abstract_t">Farias ST, Mungas D, Reed BR, et al. Progression of mild cognitive impairment to dementia in clinic- vs community-based cohorts. Arch Neurol 2009; 66:1151.</a></li><li><a class="nounderline abstract_t">Mitchell AJ, Shiri-Feshki M. Temporal trends in the long term risk of progression of mild cognitive impairment: a pooled analysis. J Neurol Neurosurg Psychiatry 2008; 79:1386.</a></li><li><a class="nounderline abstract_t">Stokholm J, Jakobsen O, Czarna JM, et al. Years of severe and isolated amnesia can precede the development of dementia in early-onset Alzheimer's disease. Neurocase 2005; 11:48.</a></li><li><a class="nounderline abstract_t">Heister D, Brewer JB, Magda S, et al. Predicting MCI outcome with clinically available MRI and CSF biomarkers. Neurology 2011; 77:1619.</a></li><li><a class="nounderline abstract_t">Pankratz VS, Roberts RO, Mielke MM, et al. Predicting the risk of mild cognitive impairment in the Mayo Clinic Study of Aging. Neurology 2015; 84:1433.</a></li><li><a class="nounderline abstract_t">DeCarli C, Mungas D, Harvey D, et al. Memory impairment, but not cerebrovascular disease, predicts progression of MCI to dementia. Neurology 2004; 63:220.</a></li><li><a class="nounderline abstract_t">Kryscio RJ, Schmitt FA, Salazar JC, et al. Risk factors for transitions from normal to mild cognitive impairment and dementia. Neurology 2006; 66:828.</a></li><li><a class="nounderline abstract_t">Tyas SL, Salazar JC, Snowdon DA, et al. Transitions to mild cognitive impairments, dementia, and death: Findings from the Nun Study. Am J Epidemiol 2007; 165:1231.</a></li><li><a class="nounderline abstract_t">Amieva H, Letenneur L, Dartigues JF, et al. Annual rate and predictors of conversion to dementia in subjects presenting mild cognitive impairment criteria defined according to a population-based study. Dement Geriatr Cogn Disord 2004; 18:87.</a></li><li><a class="nounderline abstract_t">Buerger K, Teipel SJ, Zinkowski R, et al. CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects. Neurology 2002; 59:627.</a></li><li><a class="nounderline abstract_t">Peltz CB, Corrada MM, Berlau DJ, Kawas CH. Incidence of dementia in oldest-old with amnestic MCI and other cognitive impairments. Neurology 2011; 77:1906.</a></li><li><a class="nounderline abstract_t">Saxton J, Snitz BE, Lopez OL, et al. Functional and cognitive criteria produce different rates of mild cognitive impairment and conversion to dementia. J Neurol Neurosurg Psychiatry 2009; 80:737.</a></li><li><a class="nounderline abstract_t">Amieva H, Jacqmin-Gadda H, Orgogozo JM, et al. The 9 year cognitive decline before dementia of the Alzheimer type: a prospective population-based study. Brain 2005; 128:1093.</a></li><li><a class="nounderline abstract_t">Fleisher AS, Sowell BB, Taylor C, et al. Clinical predictors of progression to Alzheimer disease in amnestic mild cognitive impairment. Neurology 2007; 68:1588.</a></li><li><a class="nounderline abstract_t">Morris JC, Storandt M, Miller JP, et al. Mild cognitive impairment represents early-stage Alzheimer disease. Arch Neurol 2001; 58:397.</a></li><li><a class="nounderline abstract_t">Sacuiu S, Sjögren M, Johansson B, et al. Prodromal cognitive signs of dementia in 85-year-olds using four sources of information. Neurology 2005; 65:1894.</a></li><li><a class="nounderline abstract_t">Laukka EJ, MacDonald SW, Bäckman L. Contrasting cognitive trajectories of impending death and preclinical dementia in the very old. Neurology 2006; 66:833.</a></li><li><a class="nounderline abstract_t">Nordlund A, Rolstad S, Klang O, et al. Two-year outcome of MCI subtypes and aetiologies in the Göteborg MCI study. J Neurol Neurosurg Psychiatry 2010; 81:541.</a></li><li><a class="nounderline abstract_t">Ganguli M, Snitz BE, Saxton JA, et al. Outcomes of mild cognitive impairment by definition: a population study. Arch Neurol 2011; 68:761.</a></li><li><a class="nounderline abstract_t">Chang YL, Bondi MW, McEvoy LK, et al. Global clinical dementia rating of 0.5 in MCI masks variability related to level of function. Neurology 2011; 76:652.</a></li><li><a class="nounderline abstract_t">Barbeau E, Didic M, Tramoni E, et al. Evaluation of visual recognition memory in MCI patients. Neurology 2004; 62:1317.</a></li><li><a class="nounderline abstract_t">Tierney MC, Yao C, Kiss A, McDowell I. Neuropsychological tests accurately predict incident Alzheimer disease after 5 and 10 years. Neurology 2005; 64:1853.</a></li><li><a class="nounderline abstract_t">Riemenschneider M, Lautenschlager N, Wagenpfeil S, et al. Cerebrospinal fluid tau and beta-amyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment. Arch Neurol 2002; 59:1729.</a></li><li><a class="nounderline abstract_t">Chen P, Ratcliff G, Belle SH, et al. Cognitive tests that best discriminate between presymptomatic AD and those who remain nondemented. Neurology 2000; 55:1847.</a></li><li><a class="nounderline abstract_t">Aggarwal NT, Wilson RS, Beck TL, et al. Mild cognitive impairment in different functional domains and incident Alzheimer's disease. J Neurol Neurosurg Psychiatry 2005; 76:1479.</a></li><li><a class="nounderline abstract_t">Pérès K, Chrysostome V, Fabrigoule C, et al. Restriction in complex activities of daily living in MCI: impact on outcome. Neurology 2006; 67:461.</a></li><li><a class="nounderline abstract_t">Sarazin M, Berr C, De Rotrou J, et al. Amnestic syndrome of the medial temporal type identifies prodromal AD: a longitudinal study. Neurology 2007; 69:1859.</a></li><li><a class="nounderline abstract_t">Dickerson BC, Sperling RA, Hyman BT, et al. Clinical prediction of Alzheimer disease dementia across the spectrum of mild cognitive impairment. Arch Gen Psychiatry 2007; 64:1443.</a></li><li><a class="nounderline abstract_t">Fleisher AS, Sun S, Taylor C, et al. Volumetric MRI vs clinical predictors of Alzheimer disease in mild cognitive impairment. Neurology 2008; 70:191.</a></li><li><a class="nounderline abstract_t">Storandt M, Grant EA, Miller JP, Morris JC. Longitudinal course and neuropathologic outcomes in original vs revised MCI and in pre-MCI. Neurology 2006; 67:467.</a></li><li><a class="nounderline abstract_t">Touchon J, Ritchie K. Prodromal cognitive disorder in Alzheimer's disease. Int J Geriatr Psychiatry 1999; 14:556.</a></li><li><a class="nounderline abstract_t">Wilson RS, Leurgans SE, Boyle PA, Bennett DA. Cognitive decline in prodromal Alzheimer disease and mild cognitive impairment. Arch Neurol 2011; 68:351.</a></li><li><a class="nounderline abstract_t">Ivnik RJ, Smith GE, Lucas JA, et al. Testing normal older people three or four times at 1- to 2-year intervals: defining normal variance. Neuropsychology 1999; 13:121.</a></li><li><a class="nounderline abstract_t">Machulda MM, Pankratz VS, Christianson TJ, et al. Practice effects and longitudinal cognitive change in normal aging vs. incident mild cognitive impairment and dementia in the Mayo Clinic Study of Aging. Clin Neuropsychol 2013; 27:1247.</a></li><li><a class="nounderline abstract_t">Palmer K, Berger AK, Monastero R, et al. Predictors of progression from mild cognitive impairment to Alzheimer disease. Neurology 2007; 68:1596.</a></li><li><a class="nounderline abstract_t">Teng E, Lu PH, Cummings JL. Neuropsychiatric symptoms are associated with progression from mild cognitive impairment to Alzheimer's disease. Dement Geriatr Cogn Disord 2007; 24:253.</a></li><li><a class="nounderline abstract_t">Goveas JS, Espeland MA, Woods NF, et al. Depressive symptoms and incidence of mild cognitive impairment and probable dementia in elderly women: The Women's Health Initiative Memory Study. J Am Geriatr Soc 2011; 59:57.</a></li><li><a class="nounderline abstract_t">Caracciolo B, Bäckman L, Monastero R, et al. The symptom of low mood in the prodromal stage of mild cognitive impairment and dementia: A cohort study of a community dwelling elderly population. J Neurol Neurosurg Psychiatry 2011; 82:788.</a></li><li><a class="nounderline abstract_t">Ramakers IH, Visser PJ, Aalten P, et al. Affective symptoms as predictors of Alzheimer's disease in subjects with mild cognitive impairment: a 10-year follow-up study. Psychol Med 2010; 40:1193.</a></li><li><a class="nounderline abstract_t">Vicini Chilovi B, Conti M, Zanetti M, et al. Differential impact of apathy and depression in the development of dementia in mild cognitive impairment patients. Dement Geriatr Cogn Disord 2009; 27:390.</a></li><li><a class="nounderline abstract_t">Panza F, Capurso C, D'Introno A, et al. Impact of depressive symptoms on the rate of progression to dementia in patients affected by mild cognitive impairment. The Italian Longitudinal Study on Aging. Int J Geriatr Psychiatry 2008; 23:726.</a></li><li><a class="nounderline abstract_t">Geda YE, Roberts RO, Mielke MM, et al. Baseline neuropsychiatric symptoms and the risk of incident mild cognitive impairment: A population-based study. Am J Psychiatry 2014; 171:572.</a></li><li><a class="nounderline abstract_t">Leoutsakos JM, Forrester SN, Lyketsos CG, Smith GS. Latent Classes of Neuropsychiatric Symptoms in NACC Controls and Conversion to Mild Cognitive Impairment or Dementia. J Alzheimers Dis 2015; 48:483.</a></li><li><a class="nounderline abstract_t">Pink A, Stokin GB, Bartley MM, et al. Neuropsychiatric symptoms, APOE ε4, and the risk of incident dementia: a population-based study. Neurology 2015; 84:935.</a></li><li><a class="nounderline abstract_t">Petersen RC, Smith GE, Ivnik RJ, et al. Apolipoprotein E status as a predictor of the development of Alzheimer's disease in memory-impaired individuals. JAMA 1995; 273:1274.</a></li><li><a class="nounderline abstract_t">Li J, Wang YJ, Zhang M, et al. Vascular risk factors promote conversion from mild cognitive impairment to Alzheimer disease. Neurology 2011; 76:1485.</a></li><li><a class="nounderline abstract_t">Wang PN, Hong CJ, Lin KN, et al. APOE ε4 increases the risk of progression from amnestic mild cognitive impairment to Alzheimer's disease among ethnic Chinese in Taiwan. J Neurol Neurosurg Psychiatry 2011; 82:165.</a></li><li><a class="nounderline abstract_t">Boyle PA, Buchman AS, Wilson RS, et al. The APOE epsilon4 allele is associated with incident mild cognitive impairment among community-dwelling older persons. Neuroepidemiology 2010; 34:43.</a></li><li><a class="nounderline abstract_t">Devanand DP, Pelton GH, Zamora D, et al. Predictive utility of apolipoprotein E genotype for Alzheimer disease in outpatients with mild cognitive impairment. Arch Neurol 2005; 62:975.</a></li><li><a class="nounderline abstract_t">Aggarwal NT, Wilson RS, Beck TL, et al. The apolipoprotein E epsilon4 allele and incident Alzheimer's disease in persons with mild cognitive impairment. Neurocase 2005; 11:3.</a></li><li><a class="nounderline abstract_t">Killiany RJ, Gomez-Isla T, Moss M, et al. Use of structural magnetic resonance imaging to predict who will get Alzheimer's disease. Ann Neurol 2000; 47:430.</a></li><li><a class="nounderline abstract_t">Elias-Sonnenschein LS, Viechtbauer W, Ramakers IH, et al. Predictive value of APOE-ε4 allele for progression from MCI to AD-type dementia: a meta-analysis. J Neurol Neurosurg Psychiatry 2011; 82:1149.</a></li><li><a class="nounderline abstract_t">Ng TP, Feng L, Nyunt MS, et al. Metabolic Syndrome and the Risk of Mild Cognitive Impairment and Progression to Dementia: Follow-up of the Singapore Longitudinal Ageing Study Cohort. JAMA Neurol 2016; 73:456.</a></li><li><a class="nounderline abstract_t">Solfrizzi V, Panza F, Colacicco AM, et al. Vascular risk factors, incidence of MCI, and rates of progression to dementia. Neurology 2004; 63:1882.</a></li><li><a class="nounderline abstract_t">Di Carlo A, Lamassa M, Baldereschi M, et al. CIND and MCI in the Italian elderly: frequency, vascular risk factors, progression to dementia. Neurology 2007; 68:1909.</a></li><li><a class="nounderline abstract_t">Simonsen AH, McGuire J, Hansson O, et al. Novel panel of cerebrospinal fluid biomarkers for the prediction of progression to Alzheimer dementia in patients with mild cognitive impairment. Arch Neurol 2007; 64:366.</a></li><li><a class="nounderline abstract_t">Palmqvist S, Zetterberg H, Mattsson N, et al. Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease. Neurology 2015; 85:1240.</a></li><li><a class="nounderline abstract_t">Maruyama M, Matsui T, Tanji H, et al. Cerebrospinal fluid tau protein and periventricular white matter lesions in patients with mild cognitive impairment: implications for 2 major pathways. Arch Neurol 2004; 61:716.</a></li><li><a class="nounderline abstract_t">Buerger K, Ewers M, Andreasen N, et al. Phosphorylated tau predicts rate of cognitive decline in MCI subjects: a comparative CSF study. Neurology 2005; 65:1502.</a></li><li><a class="nounderline abstract_t">Ewers M, Buerger K, Teipel SJ, et al. Multicenter assessment of CSF-phosphorylated tau for the prediction of conversion of MCI. Neurology 2007; 69:2205.</a></li><li><a class="nounderline abstract_t">Mattsson N, Zetterberg H, Hansson O, et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 2009; 302:385.</a></li><li><a class="nounderline abstract_t">Vemuri P, Wiste HJ, Weigand SD, et al. MRI and CSF biomarkers in normal, MCI, and AD subjects: diagnostic discrimination and cognitive correlations. Neurology 2009; 73:287.</a></li><li><a class="nounderline abstract_t">Vemuri P, Wiste HJ, Weigand SD, et al. MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change. Neurology 2009; 73:294.</a></li><li><a class="nounderline abstract_t">Mitchell AJ. CSF phosphorylated tau in the diagnosis and prognosis of mild cognitive impairment and Alzheimer's disease: a meta-analysis of 51 studies. J Neurol Neurosurg Psychiatry 2009; 80:966.</a></li><li><a class="nounderline abstract_t">De Meyer G, Shapiro F, Vanderstichele H, et al. Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. Arch Neurol 2010; 67:949.</a></li><li><a class="nounderline abstract_t">van Rossum IA, Vos SJ, Burns L, et al. Injury markers predict time to dementia in subjects with MCI and amyloid pathology. Neurology 2012; 79:1809.</a></li><li><a class="nounderline abstract_t">Skoog I, Davidsson P, Aevarsson O, et al. Cerebrospinal fluid beta-amyloid 42 is reduced before the onset of sporadic dementia: a population-based study in 85-year-olds. Dement Geriatr Cogn Disord 2003; 15:169.</a></li><li><a class="nounderline abstract_t">Moonis M, Swearer JM, Dayaw MP, et al. Familial Alzheimer disease: decreases in CSF Abeta42 levels precede cognitive decline. Neurology 2005; 65:323.</a></li><li><a class="nounderline abstract_t">Graff-Radford NR, Crook JE, Lucas J, et al. Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. Arch Neurol 2007; 64:354.</a></li><li><a class="nounderline abstract_t">Li G, Sokal I, Quinn JF, et al. CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study. Neurology 2007; 69:631.</a></li><li><a class="nounderline abstract_t">Fagan AM, Head D, Shah AR, et al. Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly. Ann Neurol 2009; 65:176.</a></li><li><a class="nounderline abstract_t">Shaw LM, Vanderstichele H, Knapik-Czajka M, et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 2009; 65:403.</a></li><li><a class="nounderline abstract_t">Snider BJ, Fagan AM, Roe C, et al. Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type. Arch Neurol 2009; 66:638.</a></li><li><a class="nounderline abstract_t">Visser PJ, Verhey F, Knol DL, et al. Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurol 2009; 8:619.</a></li><li><a class="nounderline abstract_t">Petersen RC, Aisen PS, Beckett LA, et al. Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization. Neurology 2010; 74:201.</a></li><li><a class="nounderline abstract_t">Landau SM, Harvey D, Madison CM, et al. Comparing predictors of conversion and decline in mild cognitive impairment. Neurology 2010; 75:230.</a></li><li><a class="nounderline abstract_t">Seppälä TT, Herukka SK, Hänninen T, et al. Plasma Abeta42 and Abeta40 as markers of cognitive change in follow-up: a prospective, longitudinal, population-based cohort study. J Neurol Neurosurg Psychiatry 2010; 81:1123.</a></li><li><a class="nounderline abstract_t">Lo RY, Hubbard AE, Shaw LM, et al. Longitudinal change of biomarkers in cognitive decline. Arch Neurol 2011; 68:1257.</a></li><li><a class="nounderline abstract_t">Vos SJ, Xiong C, Visser PJ, et al. Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study. Lancet Neurol 2013; 12:957.</a></li><li><a class="nounderline abstract_t">Ritchie C, Smailagic N, Noel-Storr AH, et al. Plasma and cerebrospinal fluid amyloid beta for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev 2014; :CD008782.</a></li><li><a class="nounderline abstract_t">Britschgi M, Wyss-Coray T. Blood protein signature for the early diagnosis of Alzheimer disease. Arch Neurol 2009; 66:161.</a></li><li><a class="nounderline abstract_t">Ray S, Britschgi M, Herbert C, et al. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med 2007; 13:1359.</a></li><li><a class="nounderline abstract_t">O'Bryant SE, Xiao G, Barber R, et al. A serum protein-based algorithm for the detection of Alzheimer disease. Arch Neurol 2010; 67:1077.</a></li><li><a class="nounderline abstract_t">Ovod V, Ramsey KN, Mawuenyega KG, et al. Amyloid β concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis. Alzheimers Dement 2017; 13:841.</a></li><li><a class="nounderline abstract_t">Nakamura A, Kaneko N, Villemagne VL, et al. High performance plasma amyloid-β biomarkers for Alzheimer's disease. Nature 2018; 554:249.</a></li><li><a class="nounderline abstract_t">van de Pol LA, Korf ES, van der Flier WM, et al. Magnetic resonance imaging predictors of cognition in mild cognitive impairment. Arch Neurol 2007; 64:1023.</a></li><li><a class="nounderline abstract_t">Fox NC, Crum WR, Scahill RI, et al. Imaging of onset and progression of Alzheimer's disease with voxel-compression mapping of serial magnetic resonance images. Lancet 2001; 358:201.</a></li><li><a class="nounderline abstract_t">Smith EE, Egorova S, Blacker D, et al. Magnetic resonance imaging white matter hyperintensities and brain volume in the prediction of mild cognitive impairment and dementia. Arch Neurol 2008; 65:94.</a></li><li><a class="nounderline abstract_t">Becker JT, Davis SW, Hayashi KM, et al. Three-dimensional patterns of hippocampal atrophy in mild cognitive impairment. Arch Neurol 2006; 63:97.</a></li><li><a class="nounderline abstract_t">Stewart R, Dufouil C, Godin O, et al. Neuroimaging correlates of subjective memory deficits in a community population. Neurology 2008; 70:1601.</a></li><li><a class="nounderline abstract_t">Zimmerman ME, Pan JW, Hetherington HP, et al. Hippocampal neurochemistry, neuromorphometry, and verbal memory in nondemented older adults. Neurology 2008; 70:1594.</a></li><li><a class="nounderline abstract_t">Korf ES, Wahlund LO, Visser PJ, Scheltens P. Medial temporal lobe atrophy on MRI predicts dementia in patients with mild cognitive impairment. Neurology 2004; 63:94.</a></li><li><a class="nounderline abstract_t">Geroldi C, Rossi R, Calvagna C, et al. Medial temporal atrophy but not memory deficit predicts progression to dementia in patients with mild cognitive impairment. J Neurol Neurosurg Psychiatry 2006; 77:1219.</a></li><li><a class="nounderline abstract_t">DeCarli C, Frisoni GB, Clark CM, et al. Qualitative estimates of medial temporal atrophy as a predictor of progression from mild cognitive impairment to dementia. Arch Neurol 2007; 64:108.</a></li><li><a class="nounderline abstract_t">Jack CR Jr, Bernstein MA, Fox NC, et al. The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods. J Magn Reson Imaging 2008; 27:685.</a></li><li><a class="nounderline abstract_t">Vemuri P, Wiste HJ, Weigand SD, et al. Serial MRI and CSF biomarkers in normal aging, MCI, and AD. Neurology 2010; 75:143.</a></li><li><a class="nounderline abstract_t">Stoub TR, Bulgakova M, Leurgans S, et al. MRI predictors of risk of incident Alzheimer disease: a longitudinal study. Neurology 2005; 64:1520.</a></li><li><a class="nounderline abstract_t">Mungas D, Harvey D, Reed BR, et al. Longitudinal volumetric MRI change and rate of cognitive decline. Neurology 2005; 65:565.</a></li><li><a class="nounderline abstract_t">Jack CR Jr, Shiung MM, Weigand SD, et al. Brain atrophy rates predict subsequent clinical conversion in normal elderly and amnestic MCI. Neurology 2005; 65:1227.</a></li><li><a class="nounderline abstract_t">Bell-McGinty S, Lopez OL, Meltzer CC, et al. Differential cortical atrophy in subgroups of mild cognitive impairment. Arch Neurol 2005; 62:1393.</a></li><li><a class="nounderline abstract_t">Erten-Lyons D, Howieson D, Moore MM, et al. Brain volume loss in MCI predicts dementia. Neurology 2006; 66:233.</a></li><li><a class="nounderline abstract_t">Apostolova LG, Dutton RA, Dinov ID, et al. Conversion of mild cognitive impairment to Alzheimer disease predicted by hippocampal atrophy maps. Arch Neurol 2006; 63:693.</a></li><li><a class="nounderline abstract_t">Devanand DP, Pradhaban G, Liu X, et al. Hippocampal and entorhinal atrophy in mild cognitive impairment: prediction of Alzheimer disease. Neurology 2007; 68:828.</a></li><li><a class="nounderline abstract_t">Whitwell JL, Shiung MM, Przybelski SA, et al. MRI patterns of atrophy associated with progression to AD in amnestic mild cognitive impairment. Neurology 2008; 70:512.</a></li><li><a class="nounderline abstract_t">Jack CR Jr, Weigand SD, Shiung MM, et al. Atrophy rates accelerate in amnestic mild cognitive impairment. Neurology 2008; 70:1740.</a></li><li><a class="nounderline abstract_t">Desikan RS, Fischl B, Cabral HJ, et al. MRI measures of temporoparietal regions show differential rates of atrophy during prodromal AD. Neurology 2008; 71:819.</a></li><li><a class="nounderline abstract_t">Duara R, Loewenstein DA, Potter E, et al. Medial temporal lobe atrophy on MRI scans and the diagnosis of Alzheimer disease. Neurology 2008; 71:1986.</a></li><li><a class="nounderline abstract_t">McEvoy LK, Fennema-Notestine C, Roddey JC, et al. Alzheimer disease: quantitative structural neuroimaging for detection and prediction of clinical and structural changes in mild cognitive impairment. Radiology 2009; 251:195.</a></li><li><a class="nounderline abstract_t">Henneman WJ, Sluimer JD, Barnes J, et al. Hippocampal atrophy rates in Alzheimer disease: added value over whole brain volume measures. Neurology 2009; 72:999.</a></li><li><a class="nounderline abstract_t">Davatzikos C, Xu F, An Y, et al. Longitudinal progression of Alzheimer's-like patterns of atrophy in normal older adults: the SPARE-AD index. Brain 2009; 132:2026.</a></li><li><a class="nounderline abstract_t">Desikan RS, Cabral HJ, Hess CP, et al. Automated MRI measures identify individuals with mild cognitive impairment and Alzheimer's disease. Brain 2009; 132:2048.</a></li><li><a class="nounderline abstract_t">den Heijer T, van der Lijn F, Koudstaal PJ, et al. A 10-year follow-up of hippocampal volume on magnetic resonance imaging in early dementia and cognitive decline. Brain 2010; 133:1163.</a></li><li><a class="nounderline abstract_t">Verdelho A, Madureira S, Moleiro C, et al. White matter changes and diabetes predict cognitive decline in the elderly: the LADIS study. Neurology 2010; 75:160.</a></li><li><a class="nounderline abstract_t">Koivunen J, Scheinin N, Virta JR, et al. Amyloid PET imaging in patients with mild cognitive impairment: a 2-year follow-up study. Neurology 2011; 76:1085.</a></li><li><a class="nounderline abstract_t">Kantarci K, Petersen RC, Boeve BF, et al. DWI predicts future progression to Alzheimer disease in amnestic mild cognitive impairment. Neurology 2005; 64:902.</a></li><li><a class="nounderline abstract_t">Ray KM, Wang H, Chu Y, et al. Mild cognitive impairment: apparent diffusion coefficient in regional gray matter and white matter structures. Radiology 2006; 241:197.</a></li><li><a class="nounderline abstract_t">van de Pol LA, van der Flier WM, Korf ES, et al. Baseline predictors of rates of hippocampal atrophy in mild cognitive impairment. Neurology 2007; 69:1491.</a></li><li><a class="nounderline abstract_t">Bakkour A, Morris JC, Dickerson BC. The cortical signature of prodromal AD: regional thinning predicts mild AD dementia. Neurology 2009; 72:1048.</a></li><li><a class="nounderline abstract_t">Querbes O, Aubry F, Pariente J, et al. Early diagnosis of Alzheimer's disease using cortical thickness: impact of cognitive reserve. Brain 2009; 132:2036.</a></li><li><a class="nounderline abstract_t">Caroli A, Prestia A, Galluzzi S, et al. Mild cognitive impairment with suspected nonamyloid pathology (SNAP): Prediction of progression. Neurology 2015; 84:508.</a></li><li><a class="nounderline abstract_t">Jack CR Jr, Lowe VJ, Senjem ML, et al. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain 2008; 131:665.</a></li><li><a class="nounderline abstract_t">Holland D, Brewer JB, Hagler DJ, et al. Subregional neuroanatomical change as a biomarker for Alzheimer's disease. Proc Natl Acad Sci U S A 2009; 106:20954.</a></li><li><a class="nounderline abstract_t">Jack CR Jr, Lowe VJ, Weigand SD, et al. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain 2009; 132:1355.</a></li><li><a class="nounderline abstract_t">DeCarli C, Miller BL, Swan GE, et al. Cerebrovascular and brain morphologic correlates of mild cognitive impairment in the National Heart, Lung, and Blood Institute Twin Study. Arch Neurol 2001; 58:643.</a></li><li><a class="nounderline abstract_t">Bombois S, Debette S, Delbeuck X, et al. Prevalence of subcortical vascular lesions and association with executive function in mild cognitive impairment subtypes. Stroke 2007; 38:2595.</a></li><li><a class="nounderline abstract_t">Debette S, Bombois S, Bruandet A, et al. Subcortical hyperintensities are associated with cognitive decline in patients with mild cognitive impairment. Stroke 2007; 38:2924.</a></li><li><a class="nounderline abstract_t">Kantarci K, Weigand SD, Przybelski SA, et al. Risk of dementia in MCI: combined effect of cerebrovascular disease, volumetric MRI, and 1H MRS. Neurology 2009; 72:1519.</a></li><li><a class="nounderline abstract_t">Luchsinger JA, Brickman AM, Reitz C, et al. Subclinical cerebrovascular disease in mild cognitive impairment. Neurology 2009; 73:450.</a></li><li><a class="nounderline abstract_t">Debette S, Beiser A, DeCarli C, et al. Association of MRI markers of vascular brain injury with incident stroke, mild cognitive impairment, dementia, and mortality: the Framingham Offspring Study. Stroke 2010; 41:600.</a></li><li><a class="nounderline abstract_t">Silbert LC, Dodge HH, Perkins LG, et al. Trajectory of white matter hyperintensity burden preceding mild cognitive impairment. Neurology 2012; 79:741.</a></li><li><a class="nounderline abstract_t">Staekenborg SS, Koedam EL, Henneman WJ, et al. Progression of mild cognitive impairment to dementia: contribution of cerebrovascular disease compared with medial temporal lobe atrophy. Stroke 2009; 40:1269.</a></li><li><a class="nounderline abstract_t">Bombois S, Debette S, Bruandet A, et al. Vascular subcortical hyperintensities predict conversion to vascular and mixed dementia in MCI patients. Stroke 2008; 39:2046.</a></li><li><a class="nounderline abstract_t">Lopez OL, Klunk WE, Mathis C, et al. Amyloid, neurodegeneration, and small vessel disease as predictors of dementia in the oldest-old. Neurology 2014; 83:1804.</a></li><li><a class="nounderline abstract_t">Jansen WJ, Ossenkoppele R, Knol DL, et al. Prevalence of cerebral amyloid pathology in persons without dementia: A meta-analysis. JAMA 2015; 313:1924.</a></li><li><a class="nounderline abstract_t">Wolk DA, Price JC, Saxton JA, et al. Amyloid imaging in mild cognitive impairment subtypes. Ann Neurol 2009; 65:557.</a></li><li><a class="nounderline abstract_t">Okello A, Koivunen J, Edison P, et al. Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study. Neurology 2009; 73:754.</a></li><li><a class="nounderline abstract_t">Forsberg A, Engler H, Almkvist O, et al. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging 2008; 29:1456.</a></li><li><a class="nounderline abstract_t">Resnick SM, Sojkova J, Zhou Y, et al. Longitudinal cognitive decline is associated with fibrillar amyloid-beta measured by [11C]PiB. Neurology 2010; 74:807.</a></li><li><a class="nounderline abstract_t">Small GW, Siddarth P, Kepe V, et al. Prediction of cognitive decline by positron emission tomography of brain amyloid and tau. Arch Neurol 2012; 69:215.</a></li><li><a class="nounderline abstract_t">Doraiswamy PM, Sperling RA, Coleman RE, et al. Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline: A multicenter study. Neurology 2012; 79:1636.</a></li><li><a class="nounderline abstract_t">Landau SM, Mintun MA, Joshi AD, et al. Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann Neurol 2012; 72:578.</a></li><li><a class="nounderline abstract_t">Zhang S, Smailagic N, Hyde C, et al. (11)C-PIB-PET for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev 2014; :CD010386.</a></li><li><a class="nounderline abstract_t">Wolk DA, Sadowsky C, Safirstein B, et al. Use of flutemetamol F 18-labeled positron emission tomography and other biomarkers to assess risk of clinical progression in patients with amnestic mild cognitive impairment. JAMA Neurol 2018; 75:1114.</a></li><li><a class="nounderline abstract_t">Petersen RC, Aisen P, Boeve BF, et al. Mild cognitive impairment due to Alzheimer disease in the community. Ann Neurol 2013; 74:199.</a></li><li><a class="nounderline abstract_t">Mosconi L, Perani D, Sorbi S, et al. MCI conversion to dementia and the APOE genotype: a prediction study with FDG-PET. Neurology 2004; 63:2332.</a></li><li><a class="nounderline abstract_t">Chételat G, Desgranges B, de la Sayette V, et al. Mild cognitive impairment: Can FDG-PET predict who is to rapidly convert to Alzheimer's disease? Neurology 2003; 60:1374.</a></li><li><a class="nounderline abstract_t">Anchisi D, Borroni B, Franceschi M, et al. Heterogeneity of brain glucose metabolism in mild cognitive impairment and clinical progression to Alzheimer disease. Arch Neurol 2005; 62:1728.</a></li><li><a class="nounderline abstract_t">Jagust W, Gitcho A, Sun F, et al. Brain imaging evidence of preclinical Alzheimer's disease in normal aging. Ann Neurol 2006; 59:673.</a></li><li><a class="nounderline abstract_t">Small GW, Kepe V, Ercoli LM, et al. PET of brain amyloid and tau in mild cognitive impairment. N Engl J Med 2006; 355:2652.</a></li><li><a class="nounderline abstract_t">Caselli RJ, Chen K, Lee W, et al. Correlating cerebral hypometabolism with future memory decline in subsequent converters to amnestic pre-mild cognitive impairment. Arch Neurol 2008; 65:1231.</a></li><li><a class="nounderline abstract_t">Fouquet M, Desgranges B, Landeau B, et al. Longitudinal brain metabolic changes from amnestic mild cognitive impairment to Alzheimer's disease. Brain 2009; 132:2058.</a></li><li><a class="nounderline abstract_t">Smailagic N, Vacante M, Hyde C, et al. ¹⁸F-FDG PET for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev 2015; 1:CD010632.</a></li><li><a class="nounderline abstract_t">Petersen RC. Does the source of subjects matter?: absolutely! Neurology 2010; 74:1754.</a></li><li><a class="nounderline abstract_t">Johnson KA, Schultz A, Betensky RA, et al. Tau positron emission tomographic imaging in aging and early Alzheimer disease. Ann Neurol 2016; 79:110.</a></li><li><a class="nounderline abstract_t">Brier MR, Gordon B, Friedrichsen K, et al. Tau and Aβ imaging, CSF measures, and cognition in Alzheimer's disease. Sci Transl Med 2016; 8:338ra66.</a></li><li><a class="nounderline abstract_t">Jack CR Jr, Wiste HJ, Schwarz CG, et al. Longitudinal tau PET in ageing and Alzheimer's disease. Brain 2018; 141:1517.</a></li><li><a class="nounderline abstract_t">Verghese J, Wang C, Lipton RB, Holtzer R. Motoric cognitive risk syndrome and the risk of dementia. J Gerontol A Biol Sci Med Sci 2013; 68:412.</a></li><li><a class="nounderline abstract_t">Verghese J, Annweiler C, Ayers E, et al. Motoric cognitive risk syndrome: multicountry prevalence and dementia risk. Neurology 2014; 83:718.</a></li><li><a class="nounderline abstract_t">Mielke MM, Roberts RO, Savica R, et al. Assessing the temporal relationship between cognition and gait: slow gait predicts cognitive decline in the Mayo Clinic Study of Aging. J Gerontol A Biol Sci Med Sci 2013; 68:929.</a></li><li><a class="nounderline abstract_t">Roberts RO, Christianson TJ, Kremers WK, et al. Association Between Olfactory Dysfunction and Amnestic Mild Cognitive Impairment and Alzheimer Disease Dementia. JAMA Neurol 2016; 73:93.</a></li><li><a class="nounderline abstract_t">Wilson RS, Schneider JA, Arnold SE, et al. Olfactory identification and incidence of mild cognitive impairment in older age. Arch Gen Psychiatry 2007; 64:802.</a></li><li><a class="nounderline abstract_t">Devanand DP, Lee S, Manly J, et al. Olfactory deficits predict cognitive decline and Alzheimer dementia in an urban community. Neurology 2015; 84:182.</a></li><li><a class="nounderline abstract_t">Devanand DP, Michaels-Marston KS, Liu X, et al. Olfactory deficits in patients with mild cognitive impairment predict Alzheimer's disease at follow-up. Am J Psychiatry 2000; 157:1399.</a></li><li><a class="nounderline abstract_t">Tabert MH, Liu X, Doty RL, et al. A 10-item smell identification scale related to risk for Alzheimer's disease. Ann Neurol 2005; 58:155.</a></li><li><a class="nounderline abstract_t">Yaffe K, Freimer D, Chen H, et al. Olfaction and risk of dementia in a biracial cohort of older adults. Neurology 2017; 88:456.</a></li><li><a class="nounderline abstract_t">Chertkow H, Massoud F, Nasreddine Z, et al. Diagnosis and treatment of dementia: 3. Mild cognitive impairment and cognitive impairment without dementia. CMAJ 2008; 178:1273.</a></li><li><a class="nounderline abstract_t">Gorelick PB, Scuteri A, Black SE, et al. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association/american stroke association. Stroke 2011; 42:2672.</a></li><li class="breakAll">FDA Grants Accelerated Approval for Alzheimer’s Drug. US Food and Drug Administration. Available at: https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-alzheimers-drug (Accessed on June 07, 2021).</li><li><a class="nounderline abstract_t">Zheng G, Xia R, Zhou W, et al. Aerobic exercise ameliorates cognitive function in older adults with mild cognitive impairment: a systematic review and meta-analysis of randomised controlled trials. Br J Sports Med 2016.</a></li><li><a class="nounderline abstract_t">Verhaeghen P, Marcoen A, Goossens L. Improving memory performance in the aged through mnemonic training: a meta-analytic study. Psychol Aging 1992; 7:242.</a></li><li><a class="nounderline abstract_t">Stuss DT, Robertson IH, Craik FI, et al. Cognitive rehabilitation in the elderly: a randomized trial to evaluate a new protocol. J Int Neuropsychol Soc 2007; 13:120.</a></li><li><a class="nounderline abstract_t">Troyer AK. Improving memory, knowledge, satisfaction, and functioning via an education and intervention program for older adults. Neuropsychol Dev Cogn B Aging Neuropsychol Cogn 2001; 8:256.</a></li><li><a class="nounderline abstract_t">Jean L, Bergeron ME, Thivierge S, Simard M. Cognitive intervention programs for individuals with mild cognitive impairment: systematic review of the literature. Am J Geriatr Psychiatry 2010; 18:281.</a></li><li><a class="nounderline abstract_t">Hill NT, Mowszowski L, Naismith SL, et al. Computerized Cognitive Training in Older Adults With Mild Cognitive Impairment or Dementia: A Systematic Review and Meta-Analysis. Am J Psychiatry 2017; 174:329.</a></li><li><a class="nounderline abstract_t">Russ TC, Morling JR. Cholinesterase inhibitors for mild cognitive impairment. Cochrane Database Syst Rev 2012; :CD009132.</a></li><li><a class="nounderline abstract_t">Cooper C, Li R, Lyketsos C, Livingston G. Treatment for mild cognitive impairment: systematic review. Br J Psychiatry 2013; 203:255.</a></li><li><a class="nounderline abstract_t">Tricco AC, Soobiah C, Berliner S, et al. Efficacy and safety of cognitive enhancers for patients with mild cognitive impairment: a systematic review and meta-analysis. CMAJ 2013; 185:1393.</a></li><li><a class="nounderline abstract_t">Birks J, Flicker L. Donepezil for mild cognitive impairment. Cochrane Database Syst Rev 2006; :CD006104.</a></li><li><a class="nounderline abstract_t">Lu PH, Edland SD, Teng E, et al. Donepezil delays progression to AD in MCI subjects with depressive symptoms. Neurology 2009; 72:2115.</a></li><li><a class="nounderline abstract_t">Salloway S, Ferris S, Kluger A, et al. Efficacy of donepezil in mild cognitive impairment: a randomized placebo-controlled trial. Neurology 2004; 63:651.</a></li><li><a class="nounderline abstract_t">Doody RS, Ferris SH, Salloway S, et al. Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial. Neurology 2009; 72:1555.</a></li><li><a class="nounderline abstract_t">Winblad B, Gauthier S, Scinto L, et al. Safety and efficacy of galantamine in subjects with mild cognitive impairment. Neurology 2008; 70:2024.</a></li><li><a class="nounderline abstract_t">Mayor S. Regulatory authorities review use of galantamine in mild cognitive impairment. BMJ 2005; 330:276.</a></li><li><a class="nounderline abstract_t">Feldman HH, Ferris S, Winblad B, et al. Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study. Lancet Neurol 2007; 6:501.</a></li><li><a class="nounderline abstract_t">Ströhle A, Schmidt DK, Schultz F, et al. Drug and Exercise Treatment of Alzheimer Disease and Mild Cognitive Impairment: A Systematic Review and Meta-Analysis of Effects on Cognition in Randomized Controlled Trials. Am J Geriatr Psychiatry 2015; 23:1234.</a></li><li><a class="nounderline abstract_t">Thal LJ, Ferris SH, Kirby L, et al. A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment. Neuropsychopharmacology 2005; 30:1204.</a></li><li><a class="nounderline abstract_t">DeKosky ST, Williamson JD, Fitzpatrick AL, et al. Ginkgo biloba for prevention of dementia: a randomized controlled trial. JAMA 2008; 300:2253.</a></li><li><a class="nounderline abstract_t">Snitz BE, O'Meara ES, Carlson MC, et al. Ginkgo biloba for preventing cognitive decline in older adults: a randomized trial. JAMA 2009; 302:2663.</a></li><li><a class="nounderline abstract_t">Vellas B, Coley N, Ousset PJ, et al. Long-term use of standardised Ginkgo biloba extract for the prevention of Alzheimer's disease (GuidAge): a randomised placebo-controlled trial. Lancet Neurol 2012; 11:851.</a></li><li><a class="nounderline abstract_t">Cunnane SC, Schneider JA, Tangney C, et al. Plasma and brain fatty acid profiles in mild cognitive impairment and Alzheimer's disease. J Alzheimers Dis 2012; 29:691.</a></li><li><a class="nounderline abstract_t">Mulder C, Wahlund LO, Teerlink T, et al. Decreased lysophosphatidylcholine/phosphatidylcholine ratio in cerebrospinal fluid in Alzheimer's disease. J Neural Transm (Vienna) 2003; 110:949.</a></li><li><a class="nounderline abstract_t">Trushina E, Dutta T, Persson XM, et al. Identification of altered metabolic pathways in plasma and CSF in mild cognitive impairment and Alzheimer's disease using metabolomics. PLoS One 2013; 8:e63644.</a></li><li><a class="nounderline abstract_t">Cenacchi T, Bertoldin T, Farina C, et al. Cognitive decline in the elderly: a double-blind, placebo-controlled multicenter study on efficacy of phosphatidylserine administration. Aging (Milano) 1993; 5:123.</a></li><li><a class="nounderline abstract_t">Crook TH, Tinklenberg J, Yesavage J, et al. Effects of phosphatidylserine in age-associated memory impairment. Neurology 1991; 41:644.</a></li><li><a class="nounderline abstract_t">Kato-Kataoka A, Sakai M, Ebina R, et al. Soybean-derived phosphatidylserine improves memory function of the elderly Japanese subjects with memory complaints. J Clin Biochem Nutr 2010; 47:246.</a></li><li><a class="nounderline abstract_t">Parnetti L, Amenta F, Gallai V. Choline alphoscerate in cognitive decline and in acute cerebrovascular disease: an analysis of published clinical data. Mech Ageing Dev 2001; 122:2041.</a></li><li><a class="nounderline abstract_t">Jorissen BL, Brouns F, Van Boxtel MP, et al. The influence of soy-derived phosphatidylserine on cognition in age-associated memory impairment. Nutr Neurosci 2001; 4:121.</a></li><li><a class="nounderline abstract_t">Vakhapova V, Cohen T, Richter Y, et al. Phosphatidylserine containing omega-3 fatty acids may improve memory abilities in non-demented elderly with memory complaints: a double-blind placebo-controlled trial. Dement Geriatr Cogn Disord 2010; 29:467.</a></li><li><a class="nounderline abstract_t">Soininen H, Solomon A, Visser PJ, et al. 24-month intervention with a specific multinutrient in people with prodromal Alzheimer's disease (LipiDiDiet): a randomised, double-blind, controlled trial. Lancet Neurol 2017; 16:965.</a></li><li><a class="nounderline abstract_t">Newhouse P, Kellar K, Aisen P, et al. Nicotine treatment of mild cognitive impairment: a 6-month double-blind pilot clinical trial. Neurology 2012; 78:91.</a></li><li><a class="nounderline abstract_t">Craft S, Baker LD, Montine TJ, et al. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch Neurol 2012; 69:29.</a></li><li><a class="nounderline abstract_t">Freiherr J, Hallschmid M, Frey WH 2nd, et al. Intranasal insulin as a treatment for Alzheimer's disease: a review of basic research and clinical evidence. CNS Drugs 2013; 27:505.</a></li><li><a class="nounderline abstract_t">Baker LD, Barsness SM, Borson S, et al. Effects of growth hormone–releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial. Arch Neurol 2012; 69:1420.</a></li></ol></div><div id="topicVersionRevision">Topic 5091 Version 33.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12136057" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Natural history of mild cognitive impairment in older persons.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29282327" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Practice guideline update summary: Mild cognitive impairment: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11148233" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Classification criteria for mild cognitive impairment: a population-based validation study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15249620" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Mild cognitive impairment, amnestic type: an epidemiologic study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12451203" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Incidence and outcome of mild cognitive impairment in a population-based prospective cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11870008" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Differential evolution of cognitive impairment in nondemented older persons: results from the Kungsholmen Project.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12603246" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Mild cognitive impairment: experience from a memory clinic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23019264" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Reversion from mild cognitive impairment to normal or near-normal cognition: risk factors and prognosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24353333" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Higher risk of progression to dementia in mild cognitive impairment cases who revert to normal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23019262" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Incidence of mild cognitive impairment in the Pittsburgh Cardiovascular Health Study-Cognition Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20008648" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Mild cognitive impairment: ten years later.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21893623" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Cognitive impairment: an independent predictor of excess mortality: a cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19506138" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Biracial population study of mortality in mild cognitive impairment and Alzheimer disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10190820" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Mild cognitive impairment: clinical characterization and outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16894105" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Mild cognitive impairment: risk of Alzheimer disease and rate of cognitive decline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18300306" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Frequency and course of mild cognitive impairment in a multiethnic community.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17190940" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Mild cognitive impairment: long-term course of four clinical subtypes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18347351" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Prevalence of cognitive impairment without dementia in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16864813" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Conversion to dementia from mild cognitive disorder: the Cache County Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15829527" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Vitamin E and donepezil for the treatment of mild cognitive impairment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16488378" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17030753" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Ten-year risk of dementia in subjects with mild cognitive impairment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17242334" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Conversion from subtypes of mild cognitive impairment to Alzheimer dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17353386" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Incidence of dementia in mild cognitive impairment in the cardiovascular health study cognition study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19752306" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Progression of mild cognitive impairment to dementia in clinic- vs community-based cohorts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19010949" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Temporal trends in the long term risk of progression of mild cognitive impairment: a pooled analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15804924" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Years of severe and isolated amnesia can precede the development of dementia in early-onset Alzheimer's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21998317" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Predicting MCI outcome with clinically available MRI and CSF biomarkers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25788555" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Predicting the risk of mild cognitive impairment in the Mayo Clinic Study of Aging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15277612" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Memory impairment, but not cerebrovascular disease, predicts progression of MCI to dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16567698" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Risk factors for transitions from normal to mild cognitive impairment and dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17431012" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Transitions to mild cognitive impairments, dementia, and death: findings from the Nun Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15087583" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Annual rate and predictors of conversion to dementia in subjects presenting mild cognitive impairment criteria defined according to a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12196665" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22076544" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Incidence of dementia in oldest-old with amnestic MCI and other cognitive impairments.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19279031" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Functional and cognitive criteria produce different rates of mild cognitive impairment and conversion to dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15774508" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : The 9 year cognitive decline before dementia of the Alzheimer type: a prospective population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17287448" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Clinical predictors of progression to Alzheimer disease in amnestic mild cognitive impairment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11255443" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Mild cognitive impairment represents early-stage Alzheimer disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16380609" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Prodromal cognitive signs of dementia in 85-year-olds using four sources of information.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16567699" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Contrasting cognitive trajectories of impending death and preclinical dementia in the very old.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19965857" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Two-year outcome of MCI subtypes and aetiologies in the Göteborg MCI study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21670400" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Outcomes of mild cognitive impairment by definition: a population study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21321338" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Global clinical dementia rating of 0.5 in MCI masks variability related to level of function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15111668" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Evaluation of visual recognition memory in MCI patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15955933" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Neuropsychological tests accurately predict incident Alzheimer disease after 5 and 10 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12433260" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Cerebrospinal fluid tau and beta-amyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11134384" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Cognitive tests that best discriminate between presymptomatic AD and those who remain nondemented.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16227534" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Mild cognitive impairment in different functional domains and incident Alzheimer's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16894108" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Restriction in complex activities of daily living in MCI: impact on outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17984454" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Amnestic syndrome of the medial temporal type identifies prodromal AD: a longitudinal study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18056553" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Clinical prediction of Alzheimer disease dementia across the spectrum of mild cognitive impairment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18195264" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Volumetric MRI vs clinical predictors of Alzheimer disease in mild cognitive impairment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16894109" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Longitudinal course and neuropathologic outcomes in original vs revised MCI and in pre-MCI.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10440976" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Prodromal cognitive disorder in Alzheimer's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21403020" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Cognitive decline in prodromal Alzheimer disease and mild cognitive impairment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10067783" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Testing normal older people three or four times at 1- to 2-year intervals: defining normal variance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24041121" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Practice effects and longitudinal cognitive change in normal aging vs. incident mild cognitive impairment and dementia in the Mayo Clinic Study of Aging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17485646" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Predictors of progression from mild cognitive impairment to Alzheimer disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17700021" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Neuropsychiatric symptoms are associated with progression from mild cognitive impairment to Alzheimer's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21226676" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Depressive symptoms and incidence of mild cognitive impairment and probable dementia in elderly women: the Women's Health Initiative Memory Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21212108" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : The symptom of low mood in the prodromal stage of mild cognitive impairment and dementia: a cohort study of a community dwelling elderly population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19903364" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Affective symptoms as predictors of Alzheimer's disease in subjects with mild cognitive impairment: a 10-year follow-up study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19339777" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Differential impact of apathy and depression in the development of dementia in mild cognitive impairment patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18188869" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Impact of depressive symptoms on the rate of progression to dementia in patients affected by mild cognitive impairment. The Italian Longitudinal Study on Aging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24700290" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Baseline neuropsychiatric symptoms and the risk of incident mild cognitive impairment: a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26402012" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Latent Classes of Neuropsychiatric Symptoms in NACC Controls and Conversion to Mild Cognitive Impairment or Dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25653291" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Neuropsychiatric symptoms, APOEε4, and the risk of incident dementia: a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7646655" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Apolipoprotein E status as a predictor of the development of Alzheimer's disease in memory-impaired individuals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21490316" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Vascular risk factors promote conversion from mild cognitive impairment to Alzheimer disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20660919" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : APOEε4 increases the risk of progression from amnestic mild cognitive impairment to Alzheimer's disease among ethnic Chinese in Taiwan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19907191" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : The APOE epsilon4 allele is associated with incident mild cognitive impairment among community-dwelling older persons.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15956169" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Predictive utility of apolipoprotein E genotype for Alzheimer disease in outpatients with mild cognitive impairment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15804918" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : The apolipoprotein E epsilon4 allele and incident Alzheimer's disease in persons with mild cognitive impairment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10762153" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Use of structural magnetic resonance imaging to predict who will get Alzheimer's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21493755" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Predictive value of APOE-ε4 allele for progression from MCI to AD-type dementia: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26926205" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Metabolic Syndrome and the Risk of Mild Cognitive Impairment and Progression to Dementia: Follow-up of the Singapore Longitudinal Ageing Study Cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15557506" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Vascular risk factors, incidence of MCI, and rates of progression to dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17536047" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : CIND and MCI in the Italian elderly: frequency, vascular risk factors, progression to dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17353378" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Novel panel of cerebrospinal fluid biomarkers for the prediction of progression to Alzheimer dementia in patients with mild cognitive impairment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26354982" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15148149" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Cerebrospinal fluid tau protein and periventricular white matter lesions in patients with mild cognitive impairment: implications for 2 major pathways.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16275849" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Phosphorylated tau predicts rate of cognitive decline in MCI subjects: a comparative CSF study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18071141" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Multicenter assessment of CSF-phosphorylated tau for the prediction of conversion of MCI.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19622817" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19636048" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : MRI and CSF biomarkers in normal, MCI, and AD subjects: diagnostic discrimination and cognitive correlations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19636049" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19465413" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : CSF phosphorylated tau in the diagnosis and prognosis of mild cognitive impairment and Alzheimer's disease: a meta-analysis of 51 studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20697045" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23019259" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Injury markers predict time to dementia in subjects with MCI and amyloid pathology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12584433" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Cerebrospinal fluid beta-amyloid 42 is reduced before the onset of sporadic dementia: a population-based study in 85-year-olds.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16043812" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Familial Alzheimer disease: decreases in CSF Abeta42 levels precede cognitive decline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17353377" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17698783" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19260027" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19296504" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19433664" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19523877" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20042704" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20592257" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Comparing predictors of conversion and decline in mild cognitive impairment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20478847" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Plasma Abeta42 and Abeta40 as markers of cognitive change in follow-up: a prospective, longitudinal, population-based cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21670386" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Longitudinal change of biomarkers in cognitive decline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24012374" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24913723" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Plasma and cerebrospinal fluid amyloid beta for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19064741" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Blood protein signature for the early diagnosis of Alzheimer disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17934472" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20837851" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : A serum protein-based algorithm for the detection of Alzheimer disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28734653" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Amyloidβconcentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29420472" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : High performance plasma amyloid-βbiomarkers for Alzheimer's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17620494" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Magnetic resonance imaging predictors of cognition in mild cognitive impairment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11476837" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Imaging of onset and progression of Alzheimer's disease with voxel-compression mapping of serial magnetic resonance images.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18195145" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Magnetic resonance imaging white matter hyperintensities and brain volume in the prediction of mild cognitive impairment and dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16401741" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Three-dimensional patterns of hippocampal atrophy in mild cognitive impairment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18443310" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Neuroimaging correlates of subjective memory deficits in a community population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18367703" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Hippocampal neurochemistry, neuromorphometry, and verbal memory in nondemented older adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15249617" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Medial temporal lobe atrophy on MRI predicts dementia in patients with mild cognitive impairment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16891386" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Medial temporal atrophy but not memory deficit predicts progression to dementia in patients with mild cognitive impairment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17210817" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Qualitative estimates of medial temporal atrophy as a predictor of progression from mild cognitive impairment to dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18302232" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20625167" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Serial MRI and CSF biomarkers in normal aging, MCI, and AD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15883311" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : MRI predictors of risk of incident Alzheimer disease: a longitudinal study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16116117" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Longitudinal volumetric MRI change and rate of cognitive decline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16247049" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Brain atrophy rates predict subsequent clinical conversion in normal elderly and amnestic MCI.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16157746" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Differential cortical atrophy in subgroups of mild cognitive impairment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16434660" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Brain volume loss in MCI predicts dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16682538" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Conversion of mild cognitive impairment to Alzheimer disease predicted by hippocampal atrophy maps.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17353470" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Hippocampal and entorhinal atrophy in mild cognitive impairment: prediction of Alzheimer disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17898323" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : MRI patterns of atrophy associated with progression to AD in amnestic mild cognitive impairment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18032747" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Atrophy rates accelerate in amnestic mild cognitive impairment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18672473" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : MRI measures of temporoparietal regions show differential rates of atrophy during prodromal AD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19064880" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Medial temporal lobe atrophy on MRI scans and the diagnosis of Alzheimer disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19201945" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Alzheimer disease: quantitative structural neuroimaging for detection and prediction of clinical and structural changes in mild cognitive impairment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19289740" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Hippocampal atrophy rates in Alzheimer disease: added value over whole brain volume measures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19416949" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Longitudinal progression of Alzheimer's-like patterns of atrophy in normal older adults: the SPARE-AD index.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19460794" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Automated MRI measures identify individuals with mild cognitive impairment and Alzheimer's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20375138" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : A 10-year follow-up of hippocampal volume on magnetic resonance imaging in early dementia and cognitive decline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20625169" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : White matter changes and diabetes predict cognitive decline in the elderly: the LADIS study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21325653" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Amyloid PET imaging in patients with mild cognitive impairment: a 2-year follow-up study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15753434" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : DWI predicts future progression to Alzheimer disease in amnestic mild cognitive impairment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16990677" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Mild cognitive impairment: apparent diffusion coefficient in regional gray matter and white matter structures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17923611" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : Baseline predictors of rates of hippocampal atrophy in mild cognitive impairment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19109536" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : The cortical signature of prodromal AD: regional thinning predicts mild AD dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19439419" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : Early diagnosis of Alzheimer's disease using cortical thickness: impact of cognitive reserve.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25568301" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : Mild cognitive impairment with suspected nonamyloid pathology (SNAP): Prediction of progression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18263627" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19996185" id="rid145" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>146 : Subregional neuroanatomical change as a biomarker for Alzheimer's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19339253" id="rid146" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>147 : Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11295996" id="rid147" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>148 : Cerebrovascular and brain morphologic correlates of mild cognitive impairment in the National Heart, Lung, and Blood Institute Twin Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17656658" id="rid148" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>149 : Prevalence of subcortical vascular lesions and association with executive function in mild cognitive impairment subtypes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17885256" id="rid149" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>150 : Subcortical hyperintensities are associated with cognitive decline in patients with mild cognitive impairment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19398707" id="rid150" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>151 : Risk of dementia in MCI: combined effect of cerebrovascular disease, volumetric MRI, and 1H MRS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19667320" id="rid151" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>152 : Subclinical cerebrovascular disease in mild cognitive impairment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20167919" id="rid152" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>153 : Association of MRI markers of vascular brain injury with incident stroke, mild cognitive impairment, dementia, and mortality: the Framingham Offspring Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22843262" id="rid153" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>154 : Trajectory of white matter hyperintensity burden preceding mild cognitive impairment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19228848" id="rid154" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>155 : Progression of mild cognitive impairment to dementia: contribution of cerebrovascular disease compared with medial temporal lobe atrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18436882" id="rid155" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>156 : Vascular subcortical hyperintensities predict conversion to vascular and mixed dementia in MCI patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25305156" id="rid156" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>157 : Amyloid, neurodegeneration, and small vessel disease as predictors of dementia in the oldest-old.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25988462" id="rid157" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>158 : Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19475670" id="rid158" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>159 : Amyloid imaging in mild cognitive impairment subtypes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19587325" id="rid159" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>160 : Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17499392" id="rid160" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>161 : PET imaging of amyloid deposition in patients with mild cognitive impairment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20147655" id="rid161" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>162 : Longitudinal cognitive decline is associated with fibrillar amyloid-beta measured by [11C]PiB.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22332188" id="rid162" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>163 : Prediction of cognitive decline by positron emission tomography of brain amyloid and tau.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22786606" id="rid163" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>164 : Amyloid-βassessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23109153" id="rid164" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>165 : Amyloid deposition, hypometabolism, and longitudinal cognitive decline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25052054" id="rid165" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>166 : (11)C-PIB-PET for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29799984" id="rid166" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>167 : Use of Flutemetamol F 18-Labeled Positron Emission Tomography and Other Biomarkers to Assess Risk of Clinical Progression in Patients With Amnestic Mild Cognitive Impairment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23686697" id="rid167" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>168 : Mild cognitive impairment due to Alzheimer disease in the community.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15623696" id="rid168" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>169 : MCI conversion to dementia and the APOE genotype: a prediction study with FDG-PET.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12707450" id="rid169" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>170 : Mild cognitive impairment: Can FDG-PET predict who is to rapidly convert to Alzheimer's disease?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16286547" id="rid170" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>171 : Heterogeneity of brain glucose metabolism in mild cognitive impairment and clinical progression to Alzheimer disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16470518" id="rid171" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>172 : Brain imaging evidence of preclinical Alzheimer's disease in normal aging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17182990" id="rid172" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>173 : PET of brain amyloid and tau in mild cognitive impairment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18779428" id="rid173" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>174 : Correlating cerebral hypometabolism with future memory decline in subsequent converters to amnestic pre-mild cognitive impairment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19477964" id="rid174" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>175 : Longitudinal brain metabolic changes from amnestic mild cognitive impairment to Alzheimer's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25629415" id="rid175" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>176 : ¹⁸F-FDG PET for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20484685" id="rid176" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>177 : Does the source of subjects matter?: absolutely!</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26505746" id="rid177" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>178 : Tau positron emission tomographic imaging in aging and early Alzheimer disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27169802" id="rid178" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>179 : Tau and Aβimaging, CSF measures, and cognition in Alzheimer's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29538647" id="rid179" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>180 : Longitudinal tau PET in ageing and Alzheimer's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22987797" id="rid180" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>181 : Motoric cognitive risk syndrome and the risk of dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25031288" id="rid181" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>182 : Motoric cognitive risk syndrome: multicountry prevalence and dementia risk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23250002" id="rid182" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>183 : Assessing the temporal relationship between cognition and gait: slow gait predicts cognitive decline in the Mayo Clinic Study of Aging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26569387" id="rid183" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>184 : Association Between Olfactory Dysfunction and Amnestic Mild Cognitive Impairment and Alzheimer Disease Dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17606814" id="rid184" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>185 : Olfactory identification and incidence of mild cognitive impairment in older age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25471394" id="rid185" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>186 : Olfactory deficits predict cognitive decline and Alzheimer dementia in an urban community.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10964854" id="rid186" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>187 : Olfactory deficits in patients with mild cognitive impairment predict Alzheimer's disease at follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15984022" id="rid187" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>188 : A 10-item smell identification scale related to risk for Alzheimer's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28039314" id="rid188" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>189 : Olfaction and risk of dementia in a biracial cohort of older adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18458258" id="rid189" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>190 : Diagnosis and treatment of dementia: 3. Mild cognitive impairment and cognitive impairment without dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21778438" id="rid190" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>191 : Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association/american stroke association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21778438" id="rid191" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>192 : Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association/american stroke association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27095745" id="rid192" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>193 : Aerobic exercise ameliorates cognitive function in older adults with mild cognitive impairment: a systematic review and meta-analysis of randomised controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1535198" id="rid193" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>194 : Improving memory performance in the aged through mnemonic training: a meta-analytic study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17166311" id="rid194" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>195 : Cognitive rehabilitation in the elderly: a randomized trial to evaluate a new protocol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid195" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>196 : Improving memory, knowledge, satisfaction, and functioning via an education and intervention program for older adults</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20220584" id="rid196" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>197 : Cognitive intervention programs for individuals with mild cognitive impairment: systematic review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27838936" id="rid197" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>198 : Computerized Cognitive Training in Older Adults With Mild Cognitive Impairment or Dementia: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22972133" id="rid198" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>199 : Cholinesterase inhibitors for mild cognitive impairment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24085737" id="rid199" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>200 : Treatment for mild cognitive impairment: systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24043661" id="rid200" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>201 : Efficacy and safety of cognitive enhancers for patients with mild cognitive impairment: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16856114" id="rid201" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>202 : Donepezil for mild cognitive impairment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19528519" id="rid202" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>203 : Donepezil delays progression to AD in MCI subjects with depressive symptoms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15326237" id="rid203" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>204 : Efficacy of donepezil in mild cognitive impairment: a randomized placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19176895" id="rid204" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>205 : Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18322263" id="rid205" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>206 : Safety and efficacy of galantamine in subjects with mild cognitive impairment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15695272" id="rid206" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>207 : Regulatory authorities review use of galantamine in mild cognitive impairment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17509485" id="rid207" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>208 : Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26601726" id="rid208" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>209 : Drug and Exercise Treatment of Alzheimer Disease and Mild Cognitive Impairment: A Systematic Review and Meta-Analysis of Effects on Cognition in Randomized Controlled Trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15742005" id="rid209" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>210 : A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19017911" id="rid210" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>211 : Ginkgo biloba for prevention of dementia: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20040554" id="rid211" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>212 : Ginkgo biloba for preventing cognitive decline in older adults: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22959217" id="rid212" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>213 : Long-term use of standardised Ginkgo biloba extract for the prevention of Alzheimer's disease (GuidAge): a randomised placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22466064" id="rid213" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>214 : Plasma and brain fatty acid profiles in mild cognitive impairment and Alzheimer's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12898349" id="rid214" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>215 : Decreased lysophosphatidylcholine/phosphatidylcholine ratio in cerebrospinal fluid in Alzheimer's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23700429" id="rid215" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>216 : Identification of altered metabolic pathways in plasma and CSF in mild cognitive impairment and Alzheimer's disease using metabolomics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8323999" id="rid216" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>217 : Cognitive decline in the elderly: a double-blind, placebo-controlled multicenter study on efficacy of phosphatidylserine administration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2027477" id="rid217" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>218 : Effects of phosphatidylserine in age-associated memory impairment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21103034" id="rid218" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>219 : Soybean-derived phosphatidylserine improves memory function of the elderly Japanese subjects with memory complaints.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11589921" id="rid219" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>220 : Choline alphoscerate in cognitive decline and in acute cerebrovascular disease: an analysis of published clinical data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11842880" id="rid220" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>221 : The influence of soy-derived phosphatidylserine on cognition in age-associated memory impairment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20523044" id="rid221" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>222 : Phosphatidylserine containing omega-3 fatty acids may improve memory abilities in non-demented elderly with memory complaints: a double-blind placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29097166" id="rid222" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>223 : 24-month intervention with a specific multinutrient in people with prodromal Alzheimer's disease (LipiDiDiet): a randomised, double-blind, controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22232050" id="rid223" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>224 : Nicotine treatment of mild cognitive impairment: a 6-month double-blind pilot clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21911655" id="rid224" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>225 : Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23719722" id="rid225" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>226 : Intranasal insulin as a treatment for Alzheimer's disease: a review of basic research and clinical evidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22869065" id="rid226" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>227 : Effects of growth hormone–releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
